Wayne State University
Wayne State University Dissertations
January 2021

The Advanced Applications For Optical Coherence Tomography In
Skin Imaging
Qiuyun Xu
Wayne State University

Follow this and additional works at: https://digitalcommons.wayne.edu/oa_dissertations
Part of the Biomedical Engineering and Bioengineering Commons

Recommended Citation
Xu, Qiuyun, "The Advanced Applications For Optical Coherence Tomography In Skin Imaging" (2021).
Wayne State University Dissertations. 3526.
https://digitalcommons.wayne.edu/oa_dissertations/3526

This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has
been accepted for inclusion in Wayne State University Dissertations by an authorized administrator of
DigitalCommons@WayneState.

THE ADVANCED APPLICATIONS FOR OPTICAL COHERENCE TOMOGRAPHY IN
SKIN IMAGING
by
QIUYUN XU
DISSERTATION
Submitted to the Graduate School
of Wayne State University,
Detroit, Michigan
in partial fulfillment of the requirements
for the degree of
DOCTOR OF PHILOSOPHY
2021
MAJOR: BIOMEDICAL ENGINEERING
(IMAGING DUAL TITLE)
Approved By:

Co-advisor

Date

Co-advisor

Date

DEDICATION

To my beloved parents who support me with unconditional love.
To my grandfathers with whom I can no longer share my success and joy.

ii

ACKNOWLEDGEMENTS
My highest appreciation to all the people who have helped and encouraged me along this
PhD journey.
First, I would like to thank my advisor Dr. Kamran Avanaki, who has introduced the
wonderful world of optical imaging. Thank you for providing me with an opportunity to learn
research skills and sharpen my thinking. I would also like to express my deep gratitude to my coadvisor Dr. E Mark Haacke who helped, supported, and guided me throughout my last year of
doctorate program. And it is an honor and a great pleasure for me to follow in your footsteps.
I also want to thank my committee members, Dr. Mai Lam, Dr. Zhifeng Kou, and Dr.
Gholam-Abbas Nazri, for their time and efforts on this dissertation. In addition, I want to give
special thanks to my colleagues, Dr. Rayyan Manwar, Dr. Karl Kratkiewicz, and Mohsin Zafar,
who have been wonderful friends and great support during my PhD research.
Finally, I would like to thank my dearest parents who have been a strong and constant
support during the challenges of graduate school and life. I am truly grateful for your unconditional
love, trust, and encouragement.

iii

TABLE OF CONTENTS
DEDICATION ................................................................................................................................ ii
ACKNOWLEDGEMENTS ........................................................................................................... iii
LIST OF TABLES ....................................................................................................................... viii
LIST OF FIGURES ....................................................................................................................... ix
Chapter 1 INTRODUCTION .......................................................................................................... 1
1.1 Application of Optical Coherence Tomography (OCT) in Dermatology ............................. 2
1.1.1 Overview of OCT ........................................................................................................... 2
1.1.2 Overview of Skin Structure ............................................................................................ 4
1.2 Overview of Melanoma Differential Diagnosis .................................................................... 5
1.2.1 Melanoma Development and Progression ...................................................................... 5
1.2.2 Current Clinical Diagnosis of Melanoma ....................................................................... 7
1.2.3 Diagnostic and Prognostic Biomarkers for Melanoma .................................................. 8
1.3 Using Imaging Techniques to Augment Melanoma Diagnosis .......................................... 10
1.3.1 Various Imaging Modalities Developed to Enhance Diagnosis ................................... 11
1.3.2 OCT Imaging of Melanoma ......................................................................................... 13
1.3.3 Potential Use of Molecular Imaging for Melanoma Diagnosis .................................... 14
Chapter 2 SWEPT-SOURCE OPTICAL COHERENCE TOMOGRAPHY SUPERVISED
BIOPSY ........................................................................................................................................ 16
2.1 Introduction ......................................................................................................................... 16
2.2 Materials and Methods ........................................................................................................ 18
2.2.1 OCT system configuration ........................................................................................... 18
2.2.2 Imaging needle insertion in mouse skin ....................................................................... 19
2.2.3 Needle insertion guidance using OCT .......................................................................... 19
iv

2.2.4 Punch biopsy OCT piercing tip .................................................................................... 20
2.3 Results ................................................................................................................................. 22
2.3.1 Needle in mouse skin.................................................................................................... 22
2.3.2 OCT supervised needle insertion.................................................................................. 23
2.3.3 OCT supervised punch biopsy...................................................................................... 24
2.4 Discussion ........................................................................................................................... 25
2.5 Conclusion ........................................................................................................................... 27
Chapter 3 CONTRAST-ENHANCED OPTICAL COHERENCE TOMOGRAPHY FOR
MELANOMA DETECTION: AN IN VITRO STUDY ................................................................ 28
3.1 Introduction ......................................................................................................................... 28
3.2 Materials and Methods ........................................................................................................ 30
3.2.1 OCT system configuration ........................................................................................... 30
3.2.2 Molecular probe preparation ........................................................................................ 31
3.2.3 Cell culture preparation ................................................................................................ 31
3.2.4 Data analysis ................................................................................................................. 31
3.3 Results and Discussion ........................................................................................................ 32
3.4 Conclusion ........................................................................................................................... 37
Chapter 4 MONITORING THE TOPICAL DELIVERY OF ULTRASMALL GOLD
NANOPARTICLES USING OPTICAL COHERENCE TOMOGRAPHY ................................ 38
4.1 Introduction ......................................................................................................................... 38
4.2 Dimethyl sulphoxides (DMSO) .......................................................................................... 39
4.3 Sonophoresis ....................................................................................................................... 40
4.4 Materials and Methods ........................................................................................................ 40
4.4.1 OCT system setup......................................................................................................... 40

v

4.4.2 Nanoparticles delivery on ex vivo pig skin ................................................................... 40
4.4.3 Image acquisition and processing ................................................................................. 43
4.5 Results ................................................................................................................................. 43
4.6 Discussion ........................................................................................................................... 47
4.7 Conclusion ........................................................................................................................... 48
Chapter 5 STUDY OF VARIATION OF ATTENUATION COEFFICIENT IN DIFFERENT
SKIN COLOR AND AGE GROUPS USING OPTICAL COHERENCE TOMOGRAPHY ...... 49
5.1 Introduction ......................................................................................................................... 49
5.2 Materials and Methods ........................................................................................................ 52
5.2.1 Participants ................................................................................................................... 52
5.2.2 OCT system specifications ........................................................................................... 53
5.2.3 Attenuation coefficient calculation from OCT images ................................................ 53
5.2.4 Statistical analysis ........................................................................................................ 54
5.3 Results ................................................................................................................................. 54
5.4 Discussion ........................................................................................................................... 60
5.5 Conclusion ........................................................................................................................... 63
Chapter 6 CONCLUSIONS AND FUTURE DIRECTIONS ....................................................... 64
6.1 Conclusions ......................................................................................................................... 64
6.2 Limitations and Future directions ....................................................................................... 65
APPENDIX: PRINCIPLES OF OPTICAL COHERENCE TOMOGRAPHY ............................ 67
1. Swept-Source OCT ............................................................................................................... 67
2. Axial and Lateral Resolution in OCT System ....................................................................... 68
3. Error Rate in OCT ................................................................................................................. 69
REFERENCES ............................................................................................................................. 70
vi

ABSTRACT.................................................................................................................................. 99
AUTOBIOGRAPHICAL STATEMENT ................................................................................... 101

vii

LIST OF TABLES
Table 1. The nanoparticle diffusion rate over time. NP alone diffused at 0.1144, while adding
DMSO increased the relative rate to 0.5612 and adding both DMSO and sonophoresis (US)
increased the diffusion rate to 1.0628. NP: nanoparticles, DMSO: dimethyl sulfoxide, US:
ultrasound. …………………………………………………………………………………...…..45
Table 2. Distributions of participants. ……………………………………………………………53
Table 3. Two-way ANOVA for three different age groups and skin types. ……………………....59

viii

LIST OF FIGURES
Figure 1. Principle of optical coherence tomography. ……………………………………………..3
Figure 2. The progression of melanoma. …………………………………………………………..6
Figure 3. Schematic diagram of the SS-OCT system used in this study. …………………………18
Figure 4. Demonstration of the position of the imaging plane over the inserted needle. (A) the
imaging plane parallel to the needle; (B) the imaging plane perpendicular to the needle. ………..19
Figure 5. Needle biopsy procedure is supervised using the OCT. The black line indicates the TiO2
“lesion”. ………………………………………………………………………………………….20
Figure 6. Punch biopsy probe /piercing tip. (A) picture of piercing tip; (B) schematic illustration
of piercing tip design, unit in mm; (C) front view of the probe attached to the OCT probe; (D) side
view of the probe attached to the OCT probe. …………………………………………………....21
Figure 7. Needle insertion using OCT. (A) OCT imaging of the inserted needle; (B and C) cross
section image of the needle inserting the skin; (D) side view of the needle in the skin. …………..23
Figure 8. Supervised needle biopsy using OCT. (A) Gelatin phantom used for needle biopsy; (B)
procedure of inserting needle biopsy on gelatin phantom; (C) OCT image of the needle biopsy
during the procedure. ………………………………………………………………………….…24
Figure 9. Supervised punch biopsy using OCT. (A) Gelatin phantom used for punch biopsy; (B)
procedure of punch biopsy on gelatin phantom; (C) the TiO2 “lesion” removed after punch biopsy;
(D) B-scan OCT image for the punch site during the procedure; (E) TiO2 “lesion” inside the
phantom. ………………………………………………………………………………………....25
Figure 10. The uncorrected and correct OCT image for refractive index error. (A) Uncorrected
OCT image; (B) Corrected OCT image. ………………………………………………………....26
Figure 11. Principle of tumor detection using SMART-OCT imaging. ………………………….29
Figure 12. Contrast enhanced OCT imaging of normal keratinocytes and B16-F10 melanoma cells
with Gal3-USGNPs, in vitro. (A) Contrast-enhanced B-scan OCT images of increasing
concentrations of Gal3-USGNPs; (B) Binding saturation analysis of Gal3-USGNPs; (C) same data
in a loglinear format; (D) OCT signal improvement at different incubation times; (E) Western blot
analysis of the expression level of Gal3; (F) transmission electron microscopy of USGNPs. ……34
Figure 13. Evaluation of nanoparticle aggregation on the melanoma cell surface. Bright-field
image (×40) of 4% formaldehyde fixed melanoma cells in cell culture disk mixed, (A) with dyeAB-USNPs, (B) without; (C) fluorescence microscopy images of the sample in (A); (D)
fluorescence microscopy images of sample in (B); (E) absorbance and emission spectrums of
IR800 dye as well as the accepting spectrum of the optical filter (ET775). ………………………36
ix

Figure 14. Optical coherence tomography (OCT) imaging setup and OCT images of pig ear skin.
(A) The OCT machine from Michelson DiagnosticTM (i) and imaging setup for Au NPs topical
delivery with (iii, iv) and without (ii) sonophoresis; (B) the OCT images of skin with a drop of Au
NPs on top; (C) the OCT images of skin after applying Au NPs at 0 min (i, iii, v) and 40 min (ii,
iv, vi) for no DMSO treatment and sonophoresis (i, ii), using DMSO treatment only (iii, iv), and
using DMSO treatment and sonophoresis (v, vi). Au NPs, gold nanoparticles; HSL, high speed
scanning laser ……………………………………………………………………………………42
Figure 15. The optical coherence tomography (OCT) signal changes over depth at different time
points. (A) The OCT signal at two different time points before (i) and after (ii) calibration; (B) The
OCT signal change over depth for no DMSO treatment and sonophoresis (i), using DMSO
treatment only (ii), and using DMSO treatment and sonophoresis (iii); (C) The homogeneity of pig
skin at two different time points for no DMSO treatment and sonophoresis (i), using DMSO
treatment only (ii), and using DMSO treatment and sonophoresis (iii). ………………………….46
Figure 16. Attenuation coefficient calculation from OCT images. (A) OCT image of a lateral hip
skin of 37-year-old male, with skin type II, demonstrating the skin layers including epidermis and
dermis; Fitting 1st order polynomial equation on the smoothened averaged OCT A-line in (B)
epidermis, and (C) dermis. SC: Stratum corneum (SC); DEJ: Dermoepidermal junction ………..55
Figure 17. OCT images of head and hip for different age groups and skin tone. (A) < 30 age group,
(B) 31 to 60 age group, (C) > 60 age group. ……………………………………………………...56
Figure 18. Attenuation coefficients for (A) epidermis and dermis at head; (B) epidermis and dermis
at hip; (C) epidermis at head and hip; (D) dermis at head and hip. The attenuation coefficient of
epidermis is higher than that of dermis. P<0.01 for paired t-test. The attenuation coefficient of
epidermis or dermis at head and hip shows no statistically significant difference. ……………….57
Figure 19. The mean attenuation coefficient of forehead and hip skin of different age groups and
skin types. (A) head epidermis, (B) head dermis, (C) hip epidermis, (D) hip dermis. The error bars
indicate 95% confidence interval. ……………………………………………………………..…60

x

1

Chapter 1 INTRODUCTION
Optical coherence tomography (OCT), based on low coherent interferometry, is an FDAapproved non-invasive imaging modality. It uses a low coherent near-infrared laser around the
wavelength of 1300 nm [1]. OCT has been widely used in ophthalmology to assess retina thickness
and anatomical changes. In 1997, this technology was tested to image the cross-section of human
skin in vivo, and it was able to visualize different skin layers and skin appendages [2]. Although,
OCT has great potential in monitoring skin morphologic changes, skin cancer diagnosis, and tumor
margin assessment [3], it is not well recognized and adopted by many dermatologists.
Therefore, in this research work, we aim to explore the potential clinical applications of OCT
in dermatology, especially focused on melanoma detection. We began with a brief introduction of
OCT and an overview of melanoma diagnosis in the clinic. We also discussed the application of
different imaging modalities to assist melanoma detection.
OCT can offer real-time cross-sectional images of skin with high-resolution. It is also a
contact-free and non-invasive imaging modality. Based on these unique features, OCT could aid
and improve melanoma detection in four different aspects.
First, in chapter 2, we introduced OCT as an imaging aid to assist dermatological procedures,
such as punch biopsy. Since no imaging aids are used during dermatological procedures, the
accuracy of those procedures highly depends on the training and experience of dermatologists.
Since OCT is a non-contact and real-time imaging modality, it can be used as a great visual aid to
assist the procedures and improve their accuracy.
Second, in chapter 3, we aim to improve the sensitivity and specificity of OCT for melanoma
detection. Due to the low contrast from intrinsic scattering characteristics of tissue microstructure,
OCT can not provide accurate and robust diagnosis of melanoma. Therefore, to overcome this
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limitation, we aim to use contrast agents, such as gold nanoparticles, to enhance the contrast of
OCT images and improve the accuracy of melanoma detection.
Third, in chapter 4, to ensure the non-invasive administration of contrast agent and improve
its penetration and diffusion in skin, we introduced a topical delivery method by combining
chemical and physical penetration enhancers. And OCT was used to study and compare the
delivery efficiency between different enhancers.
Fourth, in chapter 5, we aim to explore racial and age-related skin optical properties, which
serves as a fundamental understanding of skin characteristics based on OCT images. Skin optical
properties are a unique variable that depend on the degree of pigmentation, the location of the body,
and the amount of water, collagen and blood in the skin. And such information is embedded in the
OCT images. Our long term goal is to improve melanoma detection by analyzing tissue
characteristics quantitatively based on OCT images and identifying unique radiomic signatures for
future melanoma diagnosis. Hence, in this study, we extracted and quantified skin optical
properties via post processing the OCT images.
1.1 Application of Optical Coherence Tomography (OCT) in Dermatology
1.1.1 Overview of OCT
Based on the principle of light interference, OCT uses infrared low coherence length
(broadband) laser as the light source. As shown in Figure 1, the low coherence length light is split
by a coupler evenly into two optical fibers: one of the fibers directs light to the tissue sample, and
the other fiber directs light to a reference mirror [4]. The backscattered light from the tissue and
the mirror return to the beam splitter, and then merge again. The interference patterns are generated
when these two optical path lengths match [5]. Measurement of the interference pattern allows a
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precise determination of the position within the tissue. And a cross-sectional image (B-scan) is
produced by scanning the light beam across the surface of tissue.

Figure 1. Principle of optical coherence tomography.

As a new diagnostic method, its potential application in dermatology, especially in the field
of skin lesion inspections, have been evaluated by many studies [3]. The advantages for using OCT
in dermatology include moderate penetration depth, micro-scale resolution, use of near-infrared
laser, and fast real-time non-invasive imaging, which makes OCT an ideal imaging modality to
visualize the skin micro-morphology without any tissue removal.
OCT can image each layer of skin (including the epidermis, dermis, and dermoepidermal
junction (DEJ)), the skin appendages (such as hair follicles and sebaceous glands), as well as blood
vessels which are shown as low-scattering regions in the dermis of OCT images [6, 7]. As an
emerging technology, it’s potential application for skin cancer diagnosis and treatment monitoring
has been investigated by many studies [8-13]. The skin tumor cell aggregates are identifiable from
the healthy tissue due to the different backscattering coefficient of light [13]. In addition, OCT has
also been used for the tumor thickness measurement and margin assessment [14, 15].
There are commercial OCT systems available such as VivoSight (Michelson Diagnostics,
Kent, UK), Skintell (Agfa Healthcare Mortsel, Belgium and München, Germany), Callisto
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(Thorlabs, Lubeck, Germany), and NITID OCT (Dermalumics, Madrid, Spain) [16, 17]. Therefore,
as a non-invasive imaging technique, OCT can provide valuable complementary information to
the clinicians.
1.1.2 Overview of Skin Structure
As the largest organ of the body, skin has three layers, namely the epidermis, dermis, and
subcutaneous tissue (hypodermis). The epidermal thickness ranges from 77 to 267 μm, and the
dermal thickness ranges from 2115 to 5888 μm [18].
Epidermis is the superficial layer of skin, which has no blood or lymphatic vessels. It has
five layers of stratified epithelium, which are stratum corneum, stratum lucidium, stratum
granulosum, stratum spinosum, stratum basale from top to bottom [19]. The primary cell type in
epidermis is keratinocyte that produces the protein keratin. Keratin is the structural protein for
epidermis, hair, and nails. Another important cell type is melanocyte located in the stratum basale
layer. It produces the pigment melanin, which is responsible for skin and hair color and helps
protect the skin from UV radiation [20]. There are also nerve cells called Merkel cells for sensation
and immune cells called Langerhans cells in epidermis.
Dermis is composed of two layers of connective tissue, which is the papillary layer and
reticular layer from top to bottom [20]. It has no blood and lymphatic vessels, nerves, hair follicles,
and sweat glands. The primary cell type in dermis is fibroblast that produces collagen and elastin
fibers. The papillary layer intertwining with epidermis is the anchoring site for epidermis. The
epidermal extensions called rete ridges extend downward into the papillary layer. The dermal
extensions called dermal papillae extend upward into the epidermis.
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Hypodermis is served as a layer of insulation and cushion between skin and fascia [20]. It is
composed of loose connective tissue, adipose tissue, larger blood vessels and nerves. Two major
cell types are fibroblast and adipocyte. Also the fat is stored within the adipocytes in hypodermis.
1.2 Overview of Melanoma Differential Diagnosis
1.2.1 Melanoma Development and Progression
Cutaneous malignant melanoma is the most dangerous and lethal form of skin cancer, which
is still a diagnostic challenge in the dermatology clinic [21]. It is estimated that over 132,000 new
cases of melanoma will be diagnosed globally each year [22]. Melanoma begins from pigmentproducing cells, melanocytes, in the epidermis layer of skin, and progresses from the benign stage
to metastasis stage through an initial radial growth followed by a vertical growth with deeper
infiltration [23]. The transformation of melanocytes into metastatic melanoma is a very complex
process involving exogenous, endogenous, tumor-intrinsic and immune-related factors [23-25].
And a stepwise acquisition of genetic abnormalities, i.e. increased number of point mutations, has
been clearly seen during this progress [26]. Many studies have shown that B-Raf (BRAF) mutation
is a typical feature for benign nevus formation [27, 28]; additional mutation of telomerase reversetranscriptase (TERT) promoter is required for the in-situ melanoma [24, 28, 29]; the tertiary
mutations of cyclin-dependent kinase-inhibitor 2A (CDKN2A) or chromatin-remodeling are
required for invasive melanoma [30].
In clinic, based on the histopathological features, the melanoma progression is categorized
into five different phases: congenital benign nevi (a mole) with normal structural melanocytes
(Stage 0), dysplastic nevus with architectural disorder (Stage 1), early radial growth phase (Stage
2), advanced vertical growth phase with metastasis competence (Stage 3), and metastatic
melanoma (Stage 4) [31]. As shown in Figure 2, in Stage 0 and 1, melanoma is still confined to
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the epidermal region of skin, and not invasive. Stage 2 melanoma starts to grow through epidermis
into the dermis, whereas in Stage 3 melanoma the neoplastic cells populate deeper into the dermis.
As melanoma spreads into the dermis, it can invade the blood vessels and lymphatics. Finally,
Stage 4 metastatic melanoma has metastasized to other distant organs, such as distant lymph nodes,
brain, lungs, and liver [32].

Figure 2. The progression of melanoma.

For patients with early stage melanoma (Stage 0 and 1), they can be cured with surgical
excision, and have an excellent long-term survival. At least 80% of patients are free of disease for
15 years [33]. For Stage 2 melanoma, the patients can be treated with wider and deeper excision,
and a sentinel lymph node biopsy may be used to check if the cancer cells have spread to lymph
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nodes [34]. However, the 15-year survival for Stage 2 melanoma patients dropped down to 50%
[33]. For Stage 3 melanoma patients, they suffer higher risk of recurrence and metastases because
the cancer cells have spread deeper into the dermis. Surgical excision and lymph node removal
followed by additional adjuvant treatments, such as chemotherapy, radiation therapy,
immunotherapies and targeted therapies, can be used for disease management [35]. And the longterm survival for Stage 3 melanoma patients is only about 35% [33]. For patients with Stage 4
melanoma, the cancer is considered unresectable. Biopsy and imaging are used to detect the range
of metastasis. Both adjuvant treatments and clinical trials could be used for disease management
[35]. Again, for Stage 4 melanoma patients, the 2-year survival is only about 20%, and the 15-year
survival is only 10% [33].

Therefore, early diagnosis and treatment is crucial for disease

management and saving lives.
Two types of classification methods have been used to determine the stages of melanoma
[36, 37]. Cutaneous melanoma can be categorized into three stages using TNM (tumor-nodemetastasis) designations [38]. T stage stands for the primary tumor stage. Based on the vertical
depth of invasion, T stage can be subcategorized into Tis (in situ), T1, T2, T3, and T4. N stage
involves the regional lymph node. Based on the number of tumor-involved regional lymph nodes,
N stage can be subcategorized into N0, N1, N2, and N3. M stage involves the distant metastases.
With a declining prognosis, M stage can be subcategorized into M0, M1a, M1b, M1c, and M1d.
In addition to TNM classification, melanoma can also be categorized into stage I, stage II, stage
III, and stage IV, based on the localization of melanoma and the metastatic status [39].
1.2.2 Current Clinical Diagnosis of Melanoma
It has been recognized that early detection of melanoma is essential in decreasing mortality
from this malignant cancer [40, 41].
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In clinical practice, visual inspection based on the “ABCDE” rules has been used as the first
step to look for signs of melanoma. The “ABCDE” criteria stands for asymmetry, border
irregularity, color variegation, diameter greater than 6 mm, and evolving in size and shape [42].
Although the effectiveness of this approach has been confirmed, the sensitivity and specificity
range from 57% to 90% [43, 44].
Therefore, to further confirm a suspicious lesion to be melanoma, skin biopsy, as a standard
of care, must be performed for histopathological examination [38]. Key features, such as thickness
and spread of lesion, cytological atypia, pagetoid spread of melanocytes, cellular morphology,
atypical mitoses, and lymphovascular and perineural invasion, have been used to determine the
stage and extent of melanoma [45, 46]. However, skin biopsy is an invasive procedure, which can
cause pain, bleeding, scaring and other complications. Moreover, the biopsy overuse increases
expenses, the dermatology practitioners have been well trained to assure accurate examinations
and avoid unnecessary biopsies.
1.2.3 Diagnostic and Prognostic Biomarkers for Melanoma
Although histological examination remains the standard procedure for melanoma diagnosis
in clinic, researchers have invented other supplemental diagnostic methods to improve diagnostic
accuracy, such as melanoma specific biomarkers. Biomarkers are considered as molecular
signatures, which are made in response to different tumor stages or therapy. They can be expressed
in tumor cells, or secreted in fluids, such as blood and urine [47]. And both tissue-based and serumbased biomarkers have been investigated for different stages of melanoma. Although biomarkers
have great potential and value for melanoma detection, they have not been incorporated and
recommended into clinical practice [48].
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The tissue-based biomarkers can be detected by immunohistochemical staining after
biopsy. They are expressed on cell nucleus or cytoplasm [48]. In 2005, after evaluating the current
melanoma biomarkers, the investigators at The Markers and Tissue Resources for Melanoma
Meeting in Gaithersburg compiled a list of 30 melanoma biomarkers of interest, including
melanocyte inducing transcription factor (MITF), cyclin-dependent kinase inhibitor 2A (P16),
cyclin-dependent kinase inhibitor 1A (P21), galectin 3 (GAL3), proliferation marker protein Ki67 (Ki-67), mesothelin (MLSN), ADP-ribose glycohydrolase (ARH3), catenin beta-1 (CTNNB1),
interleukin-6 receptor (IL6R), signal transducer and activator of transcription 1/3 (STAT1/STAT3),
phosphatase and tensin homolog (PTEN), AKT serine/threonine kinase 1 (AKT1), pancreatic eIF2alpha kinase (pERK), secreted phosphoprotein 1 (OPN), melanoma cell adhesion molecule
(MCAM), nitric oxide synthases (iNOS), forkhead box P3 (FOXP3), CD3, CD4, vascular
endothelial growth factor (VEGF), hypoxia-inducible factor 1 (HIF-1), RELA proto-oncogene
(RelA), transmembrane 4 superfamily (TM4SF), tyrosine-protein kinase kit (c-kit) [49, 50]. These
biomarkers showed a differential expression in melanoma, and they can be detected using
formalin-fixed paraffin-embedded tissues.
The serum-based biomarkers, or serological biomarkers, are tumor-derived small
molecules constantly released into the circulatory system of cancer patients, including tumor cells,
tumor DNAs and RNAs, proteins, metabolites, and vesicles [51]. According to the updated report
from American Joint Committee on Cancer (AJCC), lactate dehydrogenase (LDH) is the only
circulating protein biomarker with prognostic value for melanoma therapies [52]. The elevated
serum LDH is associated with poor survival in stage IV melanoma and indicates negative response
to immunotherapy [53-55]. Numerous other serological biomarkers have been studied their
potential role to predict melanoma progression, including serum proteins (S100 [56], melanoma
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inhibitory activity protein (MIA) [57], VEGF [58], and interleukin-8 (CXCL8) [59]), microRNAs
(miRNA-15b, miRNA-17, miRNA-19a, miRNA-21, miRNA-33a, miRNA-126, miRNA-149,
miRNA-150, miRNA-199a-5p, and miRNA-424) [60, 61], long non-coding RNAs (SPRY4
intronic transcript 1 (SPRY4-IT1) [62], BRAF-activated non-protein coding RNA (BANCR) [63],
HOX transcript antisense RNA (HOTAIR) [64], urothelial cancer associated 1 (UCA1) [65] and
metastasis associated lung adenocarcinoma transcript 1 (MALAT-1) [66]), and circulating
melanoma cells [67-70]. Although many serological biomarkers have been proposed, limited
studies have been performed to validate their clinical application.
But unlike tissue biopsies, which are invasive and have limited tumor accessibility,
serological biomarkers can be collected from biological fluids, such as serum, blood, urine, saliva
and cerebrospinal fluid with minimal invasion [71]. Then they can be analyzed through a
repeatable liquid biopsy test. And various circulating components can be captured by liquid biopsy,
providing more comprehensive information for a patient’s cancer growth and metabolism.
Therefore, these biomarkers can be used routinely for tracking the patients response to treatment
and monitoring cancer progression. The liquid biopsy tests, Guardant360 CDx and FoundationOne
Liquid CDx, have been approved by FDA to identify specific genetic mutations in non-small cell
lung cancer, ovarian cancer, breast cancer, and prostate cancer [72, 73].
1.3 Using Imaging Techniques to Augment Melanoma Diagnosis
The current applied method for melanoma diagnosis is visual inspection followed by
histology or immunohistochemistry. To detect one melanoma, many benign lesions have to be
excised which can be time consuming and expensive. At a specialized clinic, the number of excised
lesions is about 4 for a dermatologist; but at a non-specialized clinic, this number can go up to 2040 for a general practitioner [74, 75]. In addition, the ability of clinicians to identify melanoma by
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visual inspection is variable, and the current diagnostic method is inadequate to screen large
populations. Therefore, to save the high cost of unnecessary biopsies and achieve a faster patient
management system, it’s essential to design non-invasive imaging techniques to facilitate
melanoma detection.
1.3.1 Various Imaging Modalities Developed to Enhance Diagnosis
Multiple imaging modalities have been developed and adapted to use on melanoma detection,
such as total body photography, dermoscopy, confocal microscopy, high frequency
ultrasonography, magnetic resonance imaging (MRI), positron emission tomography (PET),
spectroscopic imaging, and photoacoustic imaging.
Total body photography uses high-resolution digital camera to capture specific anatomical
sites, such as face, abdomen, chest, back, arms, legs and feet [76]. This method is most suitable to
track the evolution of pigmented lesions over time in high-risk patients, or to survey the patients
with a large number of atypical melanocytic nevi [77-80]. However, the major limitation of this
method is that it only captures the surface features of the lesions without any information about its
depth.
Dermoscopy, or epiluminescence microscopy, a hand-held magnifier with 10 to 20 folds of
magnification, has been widely used in clinical applications [81]. It uses LED for illumination and
polarized filters to decrease light reflection[82]. This allows the visualization of the subsurface
layer like papillary dermis (top layer of dermis), the vascular structures, and the distribution of
pigments [83, 84]. Several meta-analyses have proven that melanoma diagnostic accuracy can be
improved by 49% by using dermoscopy [85-87]. Also, many dermoscopy algorithms, such as
Menzies method [88], ABCD (asymmetry, border irregularity, color, diameter) system [89],
CASH method (color, architecture, symmetry, and homogeneity) [90], and 7-point checklist [91],
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have been developed and tested to improve and simplify the diagnostic process [92]. Although
dermoscopy has been a great aid for dermatologists, it requires extensive training to interpret the
dermoscopic structures, which hinders its routine use for many clinicians. More importantly, due
to its limited detection depth and resolution, dermoscopy couldn’t be used to observe the structures
within dermis and any cellular patterns.
Confocal microscopy, including reflectance confocal microscopy (RCM) or confocal
scanning laser microscopy (CSLM), has also been developed to visualize the in vivo dermal
cellular structures without a biopsy [93, 94]. Confocal microscopy utilizes a laser light source, a
condenser, an objective lens, and a detector to selectively collect the reflected light from different
depths, which allows the user to see different layers of skin. Confocal microscopy features of
melanoma have been proposed by many studies, including roundish-polygonal single cells,
polygonal cells with a dark nucleus and bright cytoplasm, oval to round bright aggregates,
broadened honeycomb pattern, mesh appearance at DEJ, ect [93-96]. VivaScope® (Caliber I.D,
Rochester, NY) is a commercial confocal microscopy that offers high resolution real-time cellularlevel images of skin [97]. However, the 200–300 µm imaging depth is the major limitation for
confocal microscopy, since this only allows the visualization of epidermis and upper dermis [98].
Also, confocal microscopy is a high-cost equipment, and it needs extensive training to interpret
the images.
High frequency ultrasonography with frequency of 3 to 100 MHz has been tested and used
in dermatology [99]. Ultrasound images display the vertical cross section of the skin. The imaging
depth and resolution depend on the frequency of ultrasound. As the frequency increases, the
penetration depth decreases, the imaging resolution increases. Lower frequency (3 – 10 MHz)
ultrasonography can image subcutaneous layer or lymph node, higher frequency (>20 MHz)
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ultrasonography can image superficial layer at a depth between 3.8 mm to 1.1 mm [100]. The 20
MHz ultrasound scanner has been mainly used for melanoma detection with good resolution (80
µm) and imaging depth (3.8 mm) [101, 102]. And on ultrasound image, melanoma was seen as
solid homogeneous hypoechoic lesion [103]. However, one common issue for ultrasound is
overestimation of melanoma thickness due to the presence of hair follicles or glands, and
lymphocytic infiltration [104, 105]. Although ultrasonography is a great aid for lymph node
examination, it cannot distinguish benign nevi and melanomas [106].
Furthermore, some other non-invasive imaging techniques, such as MRI [107], PET [108],
spectroscopic imaging [109], and photoacoustic imaging [110], have also been tested for
melanoma detection. However, MRI, PET, and spectroscopic imaging are unable to detect
melanoma at early-stage [111]. And photoacoustic imaging is still at the experimental stage and
still needs considerable improvement for future clinical application [112].
1.3.2 OCT Imaging of Melanoma
OCT has been routinely used in the eye clinic, and it was introduced in dermatological
applications since the 1990s [2, 113]. Although OCT is not able to visualize single-cell
morphology, it can display a real-time 2D cross-section of skin at a depth of 1 to 2 mm with a
resolution of 3 to 15 µm [114]. Various research has proved that OCT can clearly visualize the
sub-anatomical structures of skin, such as epidermis, dermis, epidermal dermal junction, sweat
glands, hair follicles, and blood vessels [115]. Moreover, OCT has been tested to detect nonmelanoma skin cancers like basal cell carcinoma [116-119]. Therefore, compared to the other
imaging modalities, OCT has a promising future for melanoma diagnosis.
OCT operating at the wavelength between 830 nm to 1700 nm have been used for melanoma
diagnosis. Many studies found that melanoma displays unique features in OCT images [120]. The

14

atypical melanocytes in the upper layer of epidermis and dermis have a more chaotic architectural
disarray [121-124]. More atypical cell clusters are found at the epidermal dermal junction that
distort the normal and well-defined rete ridges [122, 125, 126]. For those superficial melanoma, a
prominent feature is the upward invasion of highly reflective roundish pagetoid cells into the
epidermis from below, which is called the pagetoid growth [118, 123]. These compact infiltrations
appear as large vertical icicle-shaped structures on OCT images [122, 127]. In addition, the
vasculature of melanoma appears to be more tortuous, irregular and invasive [128, 129]. Moreover,
Moraes et al. also showed that a loss of bright collagen which appeared as a lack of hypo-reflective
bands on OCT images has a correlation with invasive melanoma [130]. And multiple studies have
reported a significant correlation between histopathological findings and OCT features [120].
Although there are only limited studies exploring melanoma diagnosis with OCT, they have
shown promising results that OCT can be used as a quick and relatively inexpensive method for
cutaneous melanoma detection and longitudinal tracking of lesion progression.
1.3.3 Potential Use of Molecular Imaging for Melanoma Diagnosis
Although these aforementioned non-invasive imaging techniques have been developed to
visualize cutaneous melanoma, they only can provide high-resolution anatomical images, and
these anatomical images alone are not enough for guiding melanoma diagnosis. As for OCT,
current studies showed that it is still difficult to differentiate melanoma from benign nevi with
OCT alone [120]. This is because the contrast of OCT images coming from the intrinsic scattering
of different tissue compartments is insufficient to tell them apart [121]. Therefore, another imaging
technique, molecular imaging, has also drawn lots of attention and been tested for melanoma
detection.
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The unique advantage for molecular imaging is its ability to visualize the expression of
specific biomolecules and quantify the biological processes at cellular levels [131]. This
information can have a huge impact on melanoma management and individualized treatment.
Another advantage for using molecular imaging on melanoma diagnosis is that it is a non-invasive
procedure, and it can potentially replace the invasive biopsy and histopathology procedures [132].
Also, the anatomical changes displayed by other imaging techniques could be discernible only at
late stage of cancer, but molecular imaging can identify and detect a diseased tumor at its early
stage [133].
Molecular imaging combines traditional imaging modalities with molecular imaging agents
to visualize and track the precise localization of a lesion [132, 134]. A variety of imaging agents
have been developed and used to visualize the activity and structure. Such imaging agents can be
oxygen, blood, and chemical molecules involved in metabolism; or a radioactive atom and isotope
for nuclear medicine; or a contrast agent such as nanoparticles, fluorophores, and dyes for optical
imaging [131]. Typically, a synthetic molecular agent consists of the targeting and signaling
components [132]. An ideal molecular probe should be specific for its target of interest and have
suitable pharmacokinetics for visualization [135, 136].
For melanoma diagnosis, the commonly used molecular imaging techniques are
lymphoscintigraphy and positron emission tomography (PET) [137]. However, these two imaging
techniques use radioactive tracers, and they are mainly used for metastatic melanoma [138].
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Chapter 2 SWEPT-SOURCE OPTICAL COHERENCE TOMOGRAPHY SUPERVISED
BIOPSY
2.1 Introduction
Skin biopsy still serves as the decisive diagnostic tool in dermatology [139]. It is an essential
procedure, in which skin samples are removed and examined under the microscope to provide
diagnostic information [46, 140]. To improve the diagnostic accuracy and to assist the
dermatologist, various imaging techniques have been added to the examination of skin [141]. To
date, several new techniques have been used to examine the skin, including reflectance confocal
microscopy (RCM), multiphoton microscopy (MPM), high-frequency ultrasonography (HFUS)
and optical coherence tomography (OCT).
RCM is the only imaging modality which has category I current procedural terminology
(CPT) reimbursement codes [142], and it has been tested and implemented to guide diagnosis [143,
144]. RCM can guide margin assessment prior to excision for lentigo maligna [145] and confirm
laser ablation of superficial and nodular basal cell carcinoma [146]. However, the main drawbacks
for RCM include high cost, large size of the device, long imaging time (20 to 30 minutes) and
limited penetration depth of 200 to 500 microns, which includes the epidermis and superficial
papillary dermis [147]. Moreover, although confocal microscopy is better established, it is still
not widely used due to the operator difficulties.
Multiphoton microscopy (MPM) is another imaging modality used to obtain cellular
morphology and extracellular matrix structure information [115, 148]. MPM can separate collagen
and elastin in extracellular matrix through differences in autofluorescence [149]. However, low
intracellular autofluorescence makes it difficult for MPM to differentiate between cancerous and
healthy cells [115].
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High-frequency ultrasonography (HFUS) is also a non-invasive, real-time imaging modality
that has been assessed in dermatology [150]. Studies have been carried out to assess skin tumors
using HFUS. But the image resolution of HFUS is relatively low [151]. While it can be used to
delineate the margins of a skin tumor, HFUS is not precise enough to distinguish the specific
diagnosis of skin lesions [152, 153].
Limitations such as coarse resolution and low penetration depth remain the major issues for
these methods. As the technologies continue to improve, there may come a time when they replace
skin biopsy. At present, skin biopsy continues to be the standard procedure for diagnosis, but noninvasive imaging modalities hold the potential to aid in skin biopsy. In this regard, optical
coherence tomography (OCT), provides safe 2D and 3D images with micrometer-scale resolution
and high penetration depth, and can be used as an imaging guide during biopsy.
OCT is a non-invasive optical imaging technique based on interferometry, which measures
backscattering of near infrared light [3]. OCT enables visualization of skin layer architecture
including stratum corneum, epidermis and dermis [154]. In addition, skin appendages, such as hair
follicles and sebaceous glands, as well as blood vessels are shown as low-scattering regions in the
dermis of OCT images [114]. OCT was introduced to study human skin in 1997. Its use
increasingly grew in skin tumor imaging, especially in the application of skin cancer diagnosis and
tumor margin assessment [3, 114, 155]. Skin tumor cell aggregates are identifiable from the
healthy tissue due to the different backscattering coefficient of light, and also in some cases the
tumor borders are detectable [114, 139]. Alawi et.al. has suggested that OCT imaging can be used
to define the tumor margin prior to excision [15].
We investigated the feasibility of using OCT imaging for real-time visualization of needle
insertion and punch biopsy techniques in both a tissue phantom and biological tissue.
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2.2 Materials and Methods
2.2.1 OCT system configuration
The OCT system used in this study is a swept-source OCT (SS-OCT) from Michelson
Diagnostic TM. The central wavelength of the laser is 1305 nm with a sweep range of 150 nm.
The penetration depth of the system was measured as 1.5 mm in healthy human skin. The images
obtained with this OCT system have a size of 5 mm × 2 mm with lateral and axial resolutions of
7.5 and 10 microns, respectively. The schematic diagram of the SS-OCT system is shown in Figure
3.

Figure 3. Schematic diagram of the SS-OCT system used in this study.
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2.2.2 Imaging needle insertion in mouse skin
A 30-gauge insulin needle was inserted into the back skin of a euthanized mouse. The back
of the mouse skin was shaved prior to the insertion. To track the movement of the needle, the
needle was held by hand and moved in and out of the skin. The OCT imaging plane was held
perpendicular as well as parallel to the needle. Figure 4 illustrates the relative position between the
imaging plane and needle.

Figure 4. Demonstration of the position of the imaging plane over the inserted needle. (A)
the imaging plane parallel to the needle; (B) the imaging plane perpendicular to the needle.

2.2.3 Needle insertion guidance using OCT
To demonstrate the utility of OCT imaging to guide the tip of a needle in reaching a target,
we utilized a gelatin phantom with the same scattering coefficient as skin. The detailed skin
scattering coefficient calculation and phantom fabrication methods are described in supplementary
material. To create a target, 10% gelatin phantom was made with a tiny dot of TiO2 powder inside
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it. India Ink, an absorber, was added to the phantom, so that the TiO2 was not visible to the naked
eye. OCT imaging was used to guide the insertion of a 30-gauge needle to reach the target. Figure
5 shows a schematic illustration of the procedure.

Figure 5. Needle biopsy procedure is supervised using the OCT. The black line indicates the
TiO2 “lesion”.

2.2.4 Punch biopsy OCT piercing tip
A probe/piercing tip was designed and fabricated to perform the imaging and punch biopsy
at the same time (Figure 6A). The piercing tip is an aluminum device that was designed to fit
tightly over the OCT handheld probe tip, so the laser will not be blocked by the metal (Figure 6C
and D). The size and schematic design was shown on Figure 6B. To perform the punch biopsy, the
sharpened piercing tip is rotated while the OCT probe remains stationary. The punch biopsy was
performed on 10% gelatin phantom. A small amount of TiO2 powder was added to the gelatin
phantom to resemble a lesion. India ink was also added in the phantom, so that the lesion can only
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be seen using OCT. After locating the lesion by OCT imaging, punch biopsy was performed
immediately by the OCT probe to remove the lesion area.

Figure 6. Punch biopsy probe /piercing tip. (A) picture of piercing tip; (B) schematic
illustration of piercing tip design, unit in mm; (C) front view of the probe attached to the
OCT probe; (D) side view of the probe attached to the OCT probe.
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2.3 Results
2.3.1 Needle in mouse skin
To test the needle insertion in real skin tissue, we performed the needle insertion in mouse
skin. A needle was inserted inside mouse skin and then imaged using OCT (Figure 7A). The mouse
skin structure, both dermis and epidermis, can be clearly seen on the OCT image. When the
imaging plane was perpendicular to the needle, the cross section of the needle was a bright halfcircle (Figure 7B). As the needle went inside the skin, the cross section of the needle appeared as
a less bright curved line (Figure 7C). The curvature decreased as the needle goes from outside to
inside the skin. When the imaging plane was parallel to the needle, the side view of the needle was
seen on OCT image. The needle inside mouse skin was shown as one bright line with a slight bend
at the air-tissue interface (Figure 7D).
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Figure 7. Needle insertion using OCT. (A) OCT imaging of the inserted needle; (B and C)
cross section image of the needle inserting the skin; (D) side view of the needle in the skin.

2.3.2 OCT supervised needle insertion
Figure 8A is the gelatin phantom with TiO2 powder to serve as a target. When a 30-gauge
insulin needle was inserted in the phantom (Figure 8B), a bright line was visualized on the OCT
image. The bright line on the image, as seen in Figure 8C, is the top outer surface of the needle.
Next, we tested the idea of supervised needle insertion using OCT. During the procedure, the tip
of the needle was used as a guide to lead the whole procedure. Figure 8C demonstrates tip of the
needle reaching the target and Supplemental Digital Content 1, which demonstrates the procedure
and corresponding OCT imaging on video.
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Figure 8. Supervised needle biopsy using OCT. (A) Gelatin phantom used for needle biopsy;
(B) procedure of inserting needle biopsy on gelatin phantom; (C) OCT image of the needle
biopsy during the procedure.

2.3.3 OCT supervised punch biopsy
To test the idea of OCT supervised punch biopsy, we performed the procedure on a gelatin
phantom using the fabricated piercing tip (Figure 9A and B). The TiO2 powder was a bright line
on the OCT image (Figure 9D). The OCT images were taken to locate the position and shape of
the suspected area (Figure 9D). The punch biopsy was performed immediately during the imaging
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to sample the “lesion” (Figure 9C). After sampling the “lesion”, we cut it open to check, and the
TiO2 powder was found inside (Figure 9E).

Figure 9. Supervised punch biopsy using OCT. (A) Gelatin phantom used for punch biopsy;
(B) procedure of punch biopsy on gelatin phantom; (C) the TiO2 “lesion” removed after
punch biopsy; (D) B-scan OCT image for the punch site during the procedure; (E) TiO2
“lesion” inside the phantom.

2.4 Discussion
In this study, we evaluated the feasibility of using OCT for supervised needle insertion and
punch biopsy. We demonstrated that the movement of needle insertion can be monitored using
OCT in real time, using mouse skin and a skin phantom. There is no time delay during the
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procedure, allowing the movement of the needle to be clearly captured by the OCT images. The
needle was a single bright line in the mouse skin (Figure 7), but appears bent at the skin surface.
This is due to the difference between the refractive index of air and skin. Refractive index is 1 in
air. The refractive index of human skin has different values for different layers of skin, ranging
from 1.37 to 1.5. In our OCT system we assume that the refractive index is constant and equals
1.3. We have devised a method to compensate for the refractive index error, and the corrected
OCT image is shown in Figure 10.

Figure 10. The uncorrected and correct OCT image for refractive index error. (A)
Uncorrected OCT image; (B) Corrected OCT image.

Due to the easy accessibility of the skin, intralesional injection is a convenient and effective
method of delivering medication. Intralesional therapy can be used for various dermatologic
diseases, including inflammatory, infectious and neoplastic [156-158]. OCT guidance will allow
visualization for more accurate drug delivery. In neoplastic disease, OCT can not only aid in the
treatment, but can also be utilized as a non-invasive means of assessing the response to treatment
[8]. Real time visualization of needle placement also holds potential in the field of cosmetic filler
injection.
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Here, we introduce OCT for image-guided skin biopsy. With OCT image guidance, biopsy
can be performed with specific targets within a lesion, or the boundaries of the lesion can be
assessed during the procedure. In large tumors, such as lentigo maligna, it is not always possible
to biopsy the lesion in its entirety. Imaging with ultraviolet light and confocal microscopy has
proven utility in biopsy and margin delineation [159, 160]. We designed a piercing tip so imaging
and biopsy can be performed at the same time. This new technique will allow the clinician to
biopsy various parts of the tumor quickly and conveniently. Imaging at the time of biopsy will also
allow the clinician to ensure that each representative morphology within the lesion is sampled. At
present, the biopsy tool is 6.8mm in diameter. In the future, the development of tools of various
sizes will expand the application of the technique. Further clinical studies to elucidate the
applications of OCT during skin procedures are indicated.
2.5 Conclusion
Optical coherence tomography holds potential not only as a diagnostic tool in dermatology,
but also to assist in procedures. OCT can provide guidance for skin injections as well as real time
imaging to assist in the performance of punch biopsy.
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Chapter 3 CONTRAST-ENHANCED OPTICAL COHERENCE TOMOGRAPHY FOR
MELANOMA DETECTION: AN IN VITRO STUDY
3.1 Introduction
Optical coherence tomography (OCT), with a high spatial resolution (<10 microns),
intermediate penetration depth (1 to 2 mm), and volumetric imaging capability has become a
popular diagnostic-assistant modality in tumor diagnosis [7]. Tissue contrast in OCT images is
generated by the intrinsic scattering characteristics of tissue that are proportional to the density,
size and shape of the tissue microstructures. Because malignant cells show pleomorphism, with
different refractive indices and absorption characteristics than normal cells, based on light-tissue
interaction theories, OCT images should discriminate malignant tissues from normal tissues and
benign neoplasms. However, the sensitivity and specificity of OCT for tumor detection and
differentiation from benign tissue is lower than anticipated. Several groups including ours have
attempted to increase the specificity by OCT image enhancement, texture analysis, even
implementing sophisticated configurations of OCT, including polarization-sensitive, phasesensitive, and dynamic OCT; these have also failed to adequately discriminate between tumor and
benign lesions [120, 161]. Therefore, novel contrast agents are needed to selectively enhance the
OCT radiomic features of the tumor and improve the diagnostic sensitivity and specificity of OCT.
In this study, we introduce the SMall nanoparticle Aggregation-enhanced Radiomics of Tumors
OCT (SMART-OCT), and evaluate its potential use for melanoma differential diagnosis in vitro.
As shown in Figure 11, the SMART-OCT approach utilizes an OCT-specific contrast agent,
which is made by conjugating ultra-small gold nanoparticles (USGNPs) to single-chain antibody
(AB). The AB specifically binds to the melanoma biomarker, which is overexpressed in melanoma,
but is absent in benign skin lesions. Therefore, after extravasation and diffusion into the tumor
tissue, the AB-USGNPs bind to the tumor cells, while the unbound fraction clears more rapidly
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and effectively to minimize background signals. Although individual unbounded AB-USGMPs
scatter the light isotropically, they only weakly reflect the scattered light back to the detector,
which is significantly attenuated. In contrast, AB-USGNPs bind to and aggregate on melanoma
cell membranes, forming much larger reflective surfaces of irregular shape and significantly reflect
back the scattered light, which considerably enhances the OCT signal.

Figure 11. Principle of tumor detection using SMART-OCT imaging

Several cell membrane biomarkers used in histopathology to differentiate malignant
melanoma from benign nevi suite our purpose, including: Galectin-3 (Gal3), Prame, p16, Nestin,
SOX2, COX2, Collagen XVII and MMP2. We choose Gal3 due to its greater expression in primary
melanoma compared to benign pigmented skin lesions [162]. Gal3 is a cellular surface protein,
expressed in benign cutaneous melanocytic lesions as well as melanoma lesions. This expression
is significantly greater in melanomas than in benign pigmented skin lesions (i.e., compound nevus,
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intradermal nevus, junctional nevus and solar lentigo) [163]. On the molecular level, Gal3
regulates autotaxin expression by modulating the expression of the transcription factor NFAT1
[164]. In addition, Gal3 directly interacts with transcription factor AP-1 and facilitates the binding
of this complex to the matrix metalloproteinase-1(MMP-1) promoter that drives MMP-1
transcription [165].
Among different types of nanoparticles, gold nanoparticles (GNPs) have been extensively
studied, largely because they are FDA approved. More importantly, GNPs are photostable, tunable
in the NIR region, nontoxic, and chemically inert for all biological processes and remain
unoxidized [166]. Moreover, biomolecules, such as antibodies can easily be conjugated to the
surface of the GNP as diagnostic agents for multiple applications. GNPs can exhibit a cytotoxic
profile, when the size is below 2 nm [167], therefore we choose to use 10 nm GNPs. The ultrasmall nanogold particles have a high labeling efficiency, fast diffusion rate, deep tumor penetration,
and efficient accumulation and extravasation [168].
3.2 Materials and Methods
3.2.1 OCT system configuration
A multi-beam, hand-held swept-source OCT system (Vivosight, Michelson Diagnostic Inc.,
Kent, United Kingdom), was used in this study. The lateral and axial resolutions are 7.5 and 10
μm, respectively. The scan area of the OCT system is 6 mm width by 6 mm length by 1.5 mm
depth (in tissue). A tunable broadband laser source with the central wavelength of 1305 and a
bandwidth of 30 nm, successively sweeps through the optical spectrum and leads the light to four
separate interferometers and forms four consecutive confocal gates.
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3.2.2 Molecular probe preparation
Gal3-USGNP conjugates were synthesized by Nano Hybrids Inc. (Austin, TX) by covalently
attaching 10 nm Gold Nanospheres via the 3.4 kDa PEG tether to Galectin-3 (B2C10) mouse IgG1
kappa light chain antibody fragment (31 kDa; sc-32790; Santa Cruz Biotechnology Inc.) using free
lysine groups.
3.2.3 Cell culture preparation
B16-F10 melanoma cells (CRL-6475™) and PCS-200-011 primary normal human
epidermal keratinocytes were obtained from ATCC. B16 melanoma cells were cultured in DMEM
+ 10% FBS + 1% NEAA + 1% Pen & Strep. PCS-200-011 keratinocytes were cultured in
Keratinocyte Growth medium (ATCC PCS-200-040) containing Extract P 0.4%, rhTGF-alpha 0.5
ng/mL, L-glutamine 6 mM, hydrocortisone 100 ng/mL, insulin 5 µg/mL, epinephrine 1.0 µM, apotransferrin 5 µg/m. These cells were used between passages 3-5. Both cell lines were seeded at the
density of 0.16 M cells/cm2 in triplicates and were left for 48 hrs to adhere and grow. Then, Gal3USGNPs were added to the cells in increasing concentrations relative to the number of cells in
culture: 103/cell, 104/cell, 105/cell, 2×105/cell, 5×105/cell, and 106/cell. Cells were incubated with
Gal3-USGNPs for 2 hrs. Cells not exposed to Gal3-USGNPs were used as a negative control. After
2 hrs, the cells were washed two times with PBS to remove the non-attached Gal3-USGNPs (to
mimic the physiologic washout over 2 hours of non-bound fraction from the tumor tissue) and the
cells were detached from the plate using Hanks solution.
3.2.4 Data analysis
A triaxial holder maintained the OCT probe fixed and perpendicular to the sample surface.
120 cross-section OCT images were collected from a 6×6×2 mm volume of medium containing
the cells. The cells that are at the same depth (±50 µm) were considered for processing. We made
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sure that the OCT objective focal point is almost at the same depth for all acquired images. Data
processing was done using Matlab (MathWorks, Terrence, CA). The OCT signal amplitude was
normalized and expressed as a fraction of maximum detectable signal (that equals 1) and expressed
as mean ± standard error.
3.3 Results and Discussion
The goal of this in vitro study was to demonstrate the ability of the proposed method for
significant differentiation between melanoma cells and nonmelanoma cells. The results in Figure
12A shows that using OCT and the contrast agent, Gal3-USGNPs conjugates, B16 melanoma cells
can be well differentiated from normal skin keratinocytes in vitro. Binding parameters of Gal3USGNPs to B16-F10 melanoma cells expressing Gal3 was determined by plotting the normalized
OCT signal intensity values over the concentration of Gal3-USGNPs/cell and fitting data in
GraphPad Prizm 4 (GraphPad, La Jolla, CA) using Hill equation for one-site saturable binding: Y
= Bmax × Xh/(Kdh + Xh), where Bmax is the maximum specific binding, Kd is the concentration of
ligand needed to achieve half maximum binding at equilibrium and h is the Hill slope.
We found that Gal3-USGNPs binding to B16-F10 melanoma cells was saturable (Figure
12B), with an apparent Bmax of 0.98 ± 0.09 and Kd of 18 093 ± 7926. In contrast, nonspecific
background OCT signals detectable from normal skin keratinocytes did not increase after
incubation even with high concentrations of Gal3-USGNPs (Bmax = 0.09 ± 0.12; Kd = 0.001 ±
0.004).
Importantly, the SMART-OCT was able to reliably discriminate B16-F10 melanoma cells
from normal keratinocytes even at the lowest concentrations of Gal3-USGNPs used in this study
(103/cell) (Figure 12C) and that the half-maximum saturation of Gal3-USGNPs to B16-F10
melanoma cells was already achieved after exposure to less than 2 × 104 particles per cell (although
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the actual number of particles bound to each melanoma cell remains to be determined). These
results are consistent with high levels of Gal3 expression in B16-F10 melanoma cells that has been
published previously by other investigators [169] and retested by us; Western blot analysis of the
expression level of Gal3 in PCS-200-011 and B16F10 melanoma cells are shown in Figure 12E.
The absence of Gal3-USGNPs signals from normal skin keratinocytes is also consistent with
previous reports about the lack of Gal3 expression in normal skin [170, 171].
To study OCT signal enhancement at different incubation times, Gal3-USGNPs were added
to the cells with a concentration of 106/cell. The results are shown in Figure 12D. It appeared that
with only 30 minutes incubation time, 87% of the maximum OCT signal is achieved, which still
yields 100% OCT signal enhancement compared to when there is no contrast-enhanced OCT
signal; this conclusion will slightly be changed in in vivo experiments when the conjugates are
administered either topically or systemically.
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Figure 12. Contrast enhanced OCT imaging of normal keratinocytes and B16-F10 melanoma
cells with Gal3-USGNPs, in vitro. (A) Contrast-enhanced B-scan OCT images of increasing
concentrations of Gal3-USGNPs; (B) Binding saturation analysis of Gal3-USGNPs; (C) same
data in a loglinear format; (D) OCT signal improvement at different incubation times; (E)
Western blot analysis of the expression level of Gal3; (F) transmission electron microscopy
of USGNPs.
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An IR800 (LI-COR 929-70 020) dye conjugated with Gal3-USGNPs (Gal3-USGNPs-IR800)
was used to test the expression of Gal-3 on melanoma cell surface. The conjugates were applied
on 4% formaldehyde fixed melanoma cells in cell culture disk. Bright-field image (×40) of 4%
formaldehyde fixed melanoma cells in cell culture disk mixed with and without dye-AB-USNPs
are shown in Figure 13A, B. The fluorescent images of the cells were taken using Fluorescence
Microscope BZ-X800 (Keyence, Inc.) with a 750 to 800 nm filter, that is, ET775. The surface of
the melanoma cells that were exposed to Gal3-USGNPs-IR800 reflected light, indicating the
attachment and aggregation of Gal3-USGNPs on the surface of the melanoma cells, while the ones
which did not expose to the conjugates, showed no reflection (see Figure 13C, D). The bright spots
in Figure 13C may be due to the aggregation of some Gal3-USGNPs that are not attached to the
melanoma cells. These initial results indicated that contrast-enhanced OCT has a great potential in
melanoma detection and differentiation of it from nonmelanoma cells.
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Figure 13. Evaluation of nanoparticle aggregation on the melanoma cell surface. Bright-field
image (×40) of 4% formaldehyde fixed melanoma cells in cell culture disk mixed, (A) with
dye-AB-USNPs, (B) without; (C) fluorescence microscopy images of the sample in (A); (D)
fluorescence microscopy images of sample in (B); (E) absorbance and emission spectrums of
IR800 dye as well as the accepting spectrum of the optical filter (ET775).

To study the accuracy ((true positive + true negative/[true positive + false negative + false
positive + true negative]) of OCT in differentiating melanoma and nonmelanoma cells, we imaged
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both PCS-200-011 and B16F10 cells, with and without contrast enhancement. The accuracy
without enhancement was 87.5% while increased 10% when contrast enhancement was utilized
with 30 minutes incubation time; increasing the incubation time or/and concentration of the
conjugates may improve the accuracy which is needed for in vivo experiments.
3.4 Conclusion
We demonstrated the ability of the SMART-OCT imaging for differentiating melanoma and
nonmelanoma cells with a high accuracy. And we believe the combination of SMART-OCT
imaging with some OCT radiomic feature extraction methodology [172], could increase the
specificity and sensitivity of OCT for tumor diagnosis.
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Chapter 4 MONITORING THE TOPICAL DELIVERY OF ULTRASMALL GOLD
NANOPARTICLES USING OPTICAL COHERENCE TOMOGRAPHY
4.1 Introduction
In dermatology, the early detection of pre-malignant and malignant lesions is crucial for
disease detection and treatment [140]. Currently, the excisional biopsy is the gold standard for skin
cancer diagnosis. However, since excisional biopsy is invasive, susceptible to sampling errors, and
can cause patient discomfort, the development of imaging-based non-invasive diagnostic
techniques with high sensitivity and specificity is gaining attention [173, 174].
Among all the imaging modalities, optical coherence tomography (OCT) has shown great
promise for skin cancer detection [3, 114]. OCT is a non-invasive and FDA approved optical
imaging technique that enables micrometer-scale imaging [139]. It is particularly promising for
dermatological applications because it provides real-time 2-D and 3-D cross sectional images of
skin subsurface structures [175, 176]. OCT is based on the principle of Michelson interferometry
and uses low coherent near infrared light at the wavelength of about 1300 nm [177]. However, the
primary limitation for using OCT in early cancer detection is the low contrast between normal and
neoplastic tissue.
To overcome this limitation, the contrast agents such as nanoparticles have been developed
and explored [178]. Various nanoparticles have been designed and invented to possess many
beneficial characteristics, such as transport vehicles for drug delivery [179, 180], contrast agent
for imaging [181, 182], and photosensitizer for photodynamic therapy [183, 184]. Specifically,
Gold nanoparticles (Au NPs) have been used as contrast agents for a variety of applications [185,
186]. Au NPs have lots of advantages as in vivo OCT contrast agents, such as biocompatibility,
and surface functionalization with additional biomolecules [187-189]. Au NPs are effective as
OCT contrast agents because of their flexible optical properties which are tailored by modifying
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the size and shape of nanoparticles [190-192]. To ensure sufficient OCT signal from Au NPs and
to improve sensitivity, it is crucial to deliver the Au NPs efficiently, evenly, and specifically to the
targeted area [193]. For dermatological applications, therefore, a topical administration is
preferable.
In our study, a commercialized OCT was used to monitor the diffusion of sub-resolution
ultrasmall 10 nm gold nanoparticles by topically applying the particles on pig ear skin which
mimics human skin. We hypothesized that DMSO and ultrasonic force would improve the
penetration and distribution of Au NPs and thus enhance topical delivery. The intensity of OCT
images over 40 minutes at different depths of skin was analyzed and compared.
4.2 Dimethyl sulphoxides (DMSO)
Dimethyl sulphoxides (DMSO) is one of the most prevalent penetration enhancers. It is a
powerful aprotic solvent which hydrogen bonds with itself rather than water. DMSO helps
facilitate diffusion through the stratum corneum, activates the formation of deposits in the dermis,
and facilitates transport into the local blood vessels. The stratum corneum acts as the major barrier
to any active substance delivered from the surface designated for deeper layers of the skin. The
four factors that influence penetration of any given material through any membrane are as follows:
(a) membrane's diffusion coefficient [194], (b) the agent's concentration in the vehicle [195], (c)
the partition coefficient between the membrane and the vehicle [196], and (d) the membrane
thickness [197]. Penetration enhancers are intended to influence all or some of these factors
without causing permanent structural or chemical modification of the membrane. Since modifying
the thickness of the membrane is not practical, most penetration agents, including DMSO, are used
to reversibly modify the factors (a) to (c). DMSO increases diffusion through the stratum corneum
by disruption of the barrier function in the stratum corneum layer, aprotic interactions with
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intercellular lipids, and reversible distortion of lipid head groups which generate a more permeable
packing

arrangement.

DMSO

also

contributes

to

partitioning

by

forming

solvent

microenvironments within the tissue. Lastly, DMSO has a solubilizing effect on less soluble agents,
improving penetration by delivering a higher concentration to the membrane barrier [198, 199].
4.3 Sonophoresis
Sonophoresis is a method that disrupts the stratum corneum lipid bilayer by facilitating the
delivery of molecules with low molecular weight through the skin. It increases the fluidity of lipids
and thus intracellular drug permeation. Sonophoresis is typically used in the form of low frequency
pressure waves < ~100 kHz. Ultrasound creates microbubbles which collapse at the surface of the
stratum corneum and produces many shock waves or acoustic microjets rendering the skin
permeable [200, 201]. Other mechanisms have been reported, including thermal effects and
radiation pressures that further add to the sonophoretic permeation enhancement [202].
4.4 Materials and Methods
4.4.1 OCT system setup
A commercialized high resolution swept-source OCT (SS-OCT) scanner with handheld
probe from Michelson Diagnostic™ was used (Figure 14A). The imaging system is FDA approved
for dermatological study, has a central wavelength of 1305 nm, and a bandwidth of 30 nm. The Aline rate is 10 kHz, and the frame rate is 6 fps. The B-scan images obtained with this OCT system
have a size of 6 × 2 mm with lateral and axial resolutions of 7.5 and 10 μm, respectively. The
penetration depth of the system was measured as 1.5 mm in healthy human skin.
4.4.2 Nanoparticles delivery on ex vivo pig skin
Pig ear skin was used due to its similarity to the human skin with particular emphasis on the
epidermal structure, thickness, and the epidermal/dermal junction. The pig ear was purchased from
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a local slaughterhouse, the skin was removed, and the hair was carefully shaved prior to the
experiments. 2 μL of 10 nm Au NPs (NanoHybrids. Inc.) was topically administered on top of the
pig skin. DMSO was used as a chemical penetration enhancer for transdermal drug delivery, and
the pig skin was treated with it (#472301, Sigma Aldrich Inc.) prior to Au NP application. 200 μL
DMSO was applied and rubbed on pig skin for 3 - 5 minutes before adding the nanoparticles on
top of that. Next, the sonophoretic method was used. After the Au NPs topically dropped on the
skin, 1 MHz sonicator (Sonifier 250, Branson) applied ultrasonic force by placing the sonicator tip
about 2 mm and 45 degree away from the Au NPs drop surface (Figure 14A, iii and iv).
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Figure 14. Optical coherence tomography (OCT) imaging setup and OCT images of pig ear
skin. (A) The OCT machine from Michelson DiagnosticTM (i) and imaging setup for Au NPs
topical delivery with (iii, iv) and without (ii) sonophoresis; (B) the OCT images of skin with
a drop of Au NPs on top; (C) the OCT images of skin after applying Au NPs at 0 min (i, iii,
v) and 40 min (ii, iv, vi) for no DMSO treatment and sonophoresis (i, ii), using DMSO
treatment only (iii, iv), and using DMSO treatment and sonophoresis (v, vi). Au NPs, gold
nanoparticles; HSL, high speed scanning laser
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4.4.3 Image acquisition and processing
The OCT probe was stably fixed using a clamp to acquire images from the same area of pig
skin, and diffusion of the nanoparticles was monitored using OCT. The first set of OCT images
were taken when the nanoparticles disappeared on the skin surface and were completely diffused
inside the skin. The second set of OCT images were taken 40 minutes later. The intensity of these
two sets of OCT images was analyzed over 13 different depths and analyzed using Matlab.
The OCT images were analyzed over 13 different depths and at two different time points. In
terms of depth, the images started from the top surface of the skin to 0.565 mm (130 pixels)
downwards with 0.044 mm (10 pixels) steps. The two time points were the disappearance of the
Au NPs on the skin surface, and 40 minutes after that.
To compensate for the effect of laser energy drop over time, the OCT signal was calibrated
at 40 minutes to the time point at which we collected the first set of images. Six areas of pig skin
without DMSO treatment and Au NPs administration were used for compensation. The mean OCT
signal intensity over 13 different depths was calculated at those two different time points. The
calibration factor for each depth was calculated as the intensity at 40 minutes divided by the
intensity at the initial time point. This calibration factor was used for all the data at 40 minutes to
correct the laser energy drop. For each depth, a region of interest (ROI) was chosen with the size
400 by 10 pixels. The mean intensity of the ROI was calculated and normalized as OCT signal
intensity. The standard deviation was calculated and normalized as the homogeneity of the ROI.
4.5 Results
The OCT monitored the Au NPs topical diffusion in real time. The results in Figure 14B
clearly show the Au NP drop on the pig skin surface. The first set of OCT images (t = 0 minute)
were acquired when the Au NPs were completely diffused inside the skin surface. The OCT probe
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was fixed during the entire imaging period to image the same location after 40 minutes (t = 40
minutes). The skin structure can be clearly seen up to 0.565 mm (130 pixels) below the top surface.
Therefore, we analyzed the OCT signal intensity of pig skin at 13 different depths with the steps
of 0.044 mm (10 pixels). Each depth is considered as one ROI with a width of 400 pixels. The
intensity of each ROI was expressed as the mean intensity value of all the pixels. The mean
intensity values were plotted over 13 different depths for two different time points t = 0 minute
(blue line) and t = 40 minutes (red line) (Figure 15A, B).
The OCT signal decreased over depth for two time points (Figure 15A, B). In Figure 15A, i,
without adding any Au NPs, the OCT signal dropped over time for the same location, especially
at depths 0.05 mm to 0.25 mm. Thus, the signal at 40 minutes for each depth was calibrated to
reach the OCT signal at initial time point (t = 0 minute) (Figure 15A, ii) and the calibration factors
were calculated and later applied to the corresponding depth.
First, the spontaneous diffusion of Au NPs on the skin surface was tested without any
enhancers. 2 μL Au NP was added on the skin surface. After the calibration, the OCT signal at 40
minutes was still lower than the signal at t = 0 minute (Figure 15B, i). On the OCT images, it is
important to note that the intensity dropped at 40 minutes (Figure 14C, ii) compared to the OCT
image at 0 minute (Figure 14C, i).
Next, two non-invasive approaches, namely DMSO and sonophoresis, were tested. DMSO
was applied and rubbed on the skin surface before adding the Au NPs. After the calibration, the
OCT signal at 40 minutes did not decrease significantly (Figure 15B, ii). The OCT signal at depth
0.044 mm and 0.088 mm dropped at 40 minutes compared to the signal at t = 0 minute. For the
following depth below 0.088 mm, however, the OCT signal at 40 minutes is higher than the signal
at t = 0 minute.
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Then, the two methods were combined. DMSO was rubbed on the skin surface first, the Au
NPs were dropped on top of skin, and then sonophoresis was administered until the Au NPs were
completely diffused inside the skin. Following calibration, the OCT signal at depth 0.044 mm and
at 40 minutes is slightly lower than the signal at t = 0 minute (Figure 15B, iii). For the depths
below 0.044 mm, the OCT signal at 40 minutes is much higher than the signal at t = 0 minute
(Figure 15B, iii). On the OCT images, the intensity of the skin increased at 40 minutes (Figure
14C, vi) compared to the OCT image at 0 minute (Figure 14C, v). The use of sonophoresis on the
DMSO treated skin greatly enhanced the results (Table 1).

NP alone
0.1144

NP + DMSO
0.5612

NP + DMSO + US
1.0628

Table 1. The nanoparticle diffusion rate over time. NP alone diffused at 0.1144, while adding
DMSO increased the relative rate to 0.5612 and adding both DMSO and sonophoresis (US)
increased the diffusion rate to 1.0628. NP: nanoparticles, DMSO: dimethyl sulfoxide, US:
ultrasound.

Additionally, the homogeneity of skin with and without enhancing methods was compared.
In Figure 15C, i, the homogeneity of skin when using Au NPs alone decreased over time. However,
the homogeneity of skin was almost unchanged over time (Figure 15C, ii, iii) when the DMSO
and sonophoresis were applied as enhancers.
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Figure 15. The optical coherence tomography (OCT) signal change over depth at different
time points. (A) The OCT signal at two different time points before (i) and after (ii)
calibration; (B) The OCT signal change over depth for no DMSO treatment and
sonophoresis (i), using DMSO treatment only (ii), and using DMSO treatment and
sonophoresis (iii); (C) The homogeneity of pig skin at two different time points for no DMSO
treatment and sonophoresis (i), using DMSO treatment only (ii), and using DMSO treatment
and sonophoresis (iii).
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4.6 Discussion
Despite a growing number of current studies involving nanomedicine in dermatology and
the cosmetic industry, the penetration and distribution of nanoparticles inside the skin requires
further investigation. Additionally, efficient delivery of Au NPs is crucial to obtain a sufficient
signal in a variety of applications. Many imaging-based techniques including light microscopy,
confocal microscopy, and electron transmission microscopy have been used to evaluate the
penetration and distribution of nanoparticles. However, these techniques are limited in penetration
depth and field of view.
Optical coherence tomography can be used to visualize nanoparticle diffusion real time
inside the skin. The OCT signal for the same location was observed to drop over approximately
40 minutes because of reduced OCT laser energy and dehydration of the skin. Since skin is excised
and exposed in the air during surgery, and the imaging period lasts 40 minutes, this dehydration
can result in an OCT signal drop. Six different areas from the skin without DMSO and Au NPs
were used in order to compensate for this effect. The calibration factors were calculated for each
depth and were applied to the corresponding depth in our analyses.
It was found that the addition of DMSO and sonophoresis increased the diffusion rate and
penetration of Au NPs in skin. Over time, the OCT signal showed an increase after using DMSO
and sonophoresis, whereas the Au NPs alone showed an OCT signal decrease. These findings
indicate that the combination of DMSO and sonophoresis may be an effective method for
nanoparticle delivery. Additionally, the topical administration can minimize the concerns of
toxicity, drug overdose, and frequent drug administration. Advances in nanotechnology such as
these have consistently expanded the field of nanomedicine in various applications.
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4.7 Conclusion
The present study demonstrates an effective approach to improve the topical delivery of gold
nanoparticles and enhance OCT image contrast. The combination of DMSO and sonophoresis was
demonstrated to be an effective method to improve the penetration and diffusion rate of gold
nanoparticles in skin. These findings may provide a new paradigm for enhancing in vivo OCT
images and, ultimately, improve the capability of OCT in the early diagnosis of cancer.
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Chapter 5 STUDY OF VARIATION OF ATTENUATION COEFFICIENT IN
DIFFERENT SKIN COLOR AND AGE GROUPS USING OPTICAL COHERENCE
TOMOGRAPHY
5.1 Introduction
Skin consists of two layers: epidermis and dermis. The stratified epidermis is primarily made
of keratinocytes. Additionally, the melanin producing cell melanocytes are also in this layer. And
melanin determines the color of skin and hair. Dermis, the underlying layer of epidermis, also has
two layers: the upper layer is papillary dermis, and the deeper one is reticular dermis [203]. Dermis
is made of collagen fibers and elastic fibers. In the papillary dermis, the collagen fibers are thinner,
more loosely arranged and wavy. Whereas, in the reticular dermis the collagen fibers are thicker,
denser, and more horizontal [204]. A younger skin is full of collagen and elastin fibers that work
together like a mesh to support its firmness and hold its shape. As one ages, these collagen and
elastin fibers begin to deteriorate, causing the appearance of fine lines, wrinkles and sagging on
the surface of the skin [20]. Some factors impact the process of aging are smoking, sun UV light,
diet, sleep, dehydration, gravity, pollution, and climate [46].
Various imaging techniques have been introduced to aid skin disease diagnosis, such as
optical coherence tomography (OCT), multispectral imaging, photoacoustic imaging, polarized
light imaging, confocal scanning laser microscopy, and ultrasound imaging [205-210]. Among all
these imaging modalities, OCT holds great potential and is gaining use and acceptance [116, 211].
It has the added benefit of providing higher resolution images due to using low coherent near
infrared light around the wavelength of 1300 nm. OCT is a non-invasive and high resolution
medical imaging technique that allows visualization of different skin layers including epidermis
and upper dermis, as well as the superficial vasculature of the skin [212-214].
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OCT can display the anatomical structure of skin, and visual examination of OCT images
could assist clinicians to diagnose many skin diseases. Moreover, OCT images also contain
information that can be extracted using some post-image processing algorithms to aid in diagnosis
[161, 215, 216]. Tissue attenuation coefficient is one of the extractable information. The
attenuation coefficient is an optical property that correlates with how easily light penetrates a tissue
after taking into account the light scattering and absorption [203, 217, 218]. A large attenuation
coefficient indicates a quick exponential decrease of incident light with depth which happens in
highly scattering or absorbing tissue types, and small attenuation happens when the tissue sample
has low absorption and weakly scattering properties [219, 220]. Therefore, the attenuation
coefficient could give us a better understanding of the skin composition and condition.
The optical attenuation coefficient has been used as a quantitative measurement of tissue
optical properties. It reflects the optical properties of different tissues or the tissues with different
abnormalities. The depth-resolved attenuation coefficient of OCT signal is one extension of OCT.
Vermeer et al. developed a model-based method to spatially resolve the attenuation coefficient for
each pixel from an ocular OCT image. It was shown that this method can effectively remove
common OCT image shadowing artifacts [221]. Amaral et al. developed a new model to estimate
the depth-resolved attenuation coefficient using OCT for thin and membrane-like structure, i.e.
tympanum. The obtained OCT image is based on the tissue optical properties instead of intensity,
which has additional benefit for tissue differentiation [222]. Liu et al. developed an optimized
depth-resolved estimation method to estimate the attenuation coefficient from OCT signals. They
showed that this optimized method can calculate attenuation coefficient at any depth, even though
the light is completely attenuated. They applied this method in OCT angiography to detect cerebral
damage [223]. Since the attenuation coefficient reflects tissue properties at different depths, it has
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been used for OCT image segmentation, such as retinal pigment epithelium, choroidal stroma, and
lamina cribrosa [224, 225]. In addition, the attenuation coefficient measured from OCT signal has
also been used for tissue discrimination. Freek et al. measured the intrinsic attenuation coefficient
of atherosclerotic tissue. They proposed that such quantitative analysis of OCT image can be used
to discrimination between plaque constituents and different plaque types [226]. Xu et al. used the
attenuation coefficient as a quantitative OCT feature to enhance the differentiation between fibrous,
lipid and calcific atherosclerotic plaques [227]. Xu et al. showed that the viscous properties during
blood coagulation is related to the changes of attenuation coefficient. And OCT can be used to
monitor the blood coagulation status by measuring the viscosity-related attenuation coefficient
[228]. Ali et al. developed an enhancement algorithm for OCT skin images by using skin layer
detection and attenuation coefficient compensation. In this study, the attenuation coefficients of
different skin layers are estimated based on the exponential decay of light optical power. The
results show that the attenuation compensation algorithm can increase the SNR and image contrast
[229].
We propose that the attenuation coefficient will be influenced by differences in skin type
(due to different amounts of melanin in the tissue [230]) and age (due to the integrity and density
of collagen and elastin fibers [231]). By analyzing the attenuation coefficient, we develop a
baseline of this property in different skin types and at different ages which may assist in correct
utility of analyzing this property in the diagnosis of various skin diseases, including skin cancer.
In our study, we quantified the skin attenuation coefficient for different skin type and different
ages using OCT and studied the change of attenuation coefficient between epidermis and dermis,
and between head and hip as well.
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5.2 Materials and Methods
5.2.1 Participants
Individuals with healthy skin on the forehead between the ages of 1 and 100 were eligible to
participate in the study (see Table 2 for the distribution of participants based on age and skin type).
Participants are asked about their response to sun exposure regarding tanning and burning to
determine their Fitzpatrick skin type. Fitzpatrick skin photo type is a numerical classification
system based on a person's skin color, degree of sun burning and tanning, which is determined by
the amount of melanin pigment in their skin [232]. The participants were categorized in 3 different
age groups, from <30, 31 to 60, and >60. The participants were also divided into 3 different skin
type groups based on their Fitzpatrick skin type: I & II, III & IV, and V & VI. OCT images were
collected from their forehead and hip. The attenuation coefficient from both epidermis and dermis
were calculated and averaged separately.
Inclusion criteria were as follows: (i) age 18 years or older; (ii) able to provide written
informed consent prior to any trial related procedure. The exclusion criteria were as follows: (i)
failure to give written informed consent; (ii) skin not intact (e.g., open sores, ulcers, bleeding); (iii)
lesion containing foreign matter (e.g., tattoo ink, splinter, marker).
All the participants were recruited at the Oakwood Hospital. All the imaging procedures and
experimental protocols were approved and carried out according to the guidelines of the Wayne
State's Institutional Review Board (IRB #: 061818MP4E). Written informed consent was obtained
from all subjects before enrollment in the study. The patients neither refused to sign the written
informed consent nor were excluded from the study.
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FITZPATRICK TYPE
I and II
III and IV
V and VI
TOTALS

<30
3
16
11
30

AGE
31-60 >60 TOTALS
10
11
24
18
10
44
15
6
32
43
27
100

Table 2. Distributions of participants.

5.2.2 OCT system specifications
We use a swept-source OCT system (SS-OCT) (VivoSight, Michelson Diagnostic™ Inc.,
United Kingdom) for this study. The swept source laser is with the central wavelength of
1305±15nm.The lateral and axial resolutions are 7.5 μm and 5 μm, respectively. The scan area of
the OCT system is 6 mm (width) × 6 mm (length) × 2 mm (depth).
5.2.3 Attenuation coefficient calculation from OCT images
Loss of light in tissue can be caused by absorption, scattering, or a combination of both.
When propagating through a medium, the irradiance of the light beam follows the equation: 𝐼(𝑧) ∝
𝑒 −𝜇𝑎∗𝑧 , where µa is the attenuation coefficient, and z is the depth. Fitting an exponential curve to
the averaged OCT A-line (or sometimes smoothed averaged A-line) in a region of interest (ROI)
is a commonly used method to calculate the attenuation coefficients from OCT images [233]. For
the fitting, a built-in function “fit” in Matlab was used, in which the Levenberg–Marquardt leastsquare method was used. This function adjusts the attenuation coefficient in the equation above in
order to obtain a curve that best fits the (smoothed) averaged A-lines.
Three sets of OCT images from each participant were chosen for analysis. In each set, five
different ROIs were selected from the epidermis and five from the dermis. The values from five
ROIs (in all three sets) were averaged to get the final attenuation coefficient of epidermis or dermis
of each participant.
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5.2.4 Statistical analysis
Descriptive statistics such as mean and standard deviations were provided for continuous
endpoint. Comparison between groups of patients by age and skin type were made by two-way
ANOVA. Repeated measurements from different locations (forehead vs. hip) and skin layers
(epidermis vs. dermis) were averaged for each patient for the ANOVA analysis. If the global tests
were significant, pairwise comparison tests were performed with Tukey HSD adjustment for
multiple testing. Comparison between forehead and hip or epidermis and dermis were performed
with paired T test. All statistical analysis was carried out at a 5% level significance. The statistical
analysis was carried out using SPSS software (version 17.0; SPSS, Chicago, IL, USA).
5.3 Results
As shown in Figure 16, skin structures, such as epidermis, dermis, stratum corneum (SC),
and dermoepidermal junction (DEJ), are clearly discernible on OCT images. The averaged A-line
from the selected ROI is calculated and plotted as a function of pixels in axial direction. The first
order linear fit is applied to the smoothened average A-line.
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Figure 16. Attenuation coefficient calculation from OCT images. (A) OCT image of a lateral
hip skin of 37-year-old male, with skin type II, demonstrating the skin layers including
epidermis and dermis; Fitting 1st order polynomial equation on the smoothened averaged
OCT A-line in (B) epidermis, and (C) dermis. SC: Stratum corneum (SC); DEJ:
Dermoepidermal junction

The OCT images from three different age groups, dark vs. light skin, and head vs. hip were
shown in Figure 17. It is difficult to tell the skin structural differences among three different age
groups. Comparing the structural differences between light and dark skin, the DEJ for dark skin
appears less obvious. However, comparing the OCT images of head and hip, we noticed that the
vasculatures were more apparent on the hip OCT images than on the head ones.
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Figure 17. OCT images of head and hip for different age groups and skin tone. (A) < 30 age
group, (B) 31 to 60 age group, (C) > 60 age group.

Paired sample t-test revealed there is a significant difference when comparing the attenuation
coefficient between epidermis and dermis, both in head and hip (Figure 18A, B). But there is no
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significant variation in attenuation coefficient within the epidermises at head or hip (Figure 18C,
D). The error bars indicate 95% confidence interval.

Figure 18. Attenuation coefficients for (A) epidermis and dermis at head; (B) epidermis and
dermis at hip; (C) epidermis at head and hip; (D) dermis at head and hip. The attenuation
coefficient of epidermis is higher than that of dermis. P<0.01 for paired t-test. The
attenuation coefficient of epidermis or dermis at head and hip shows no statistically
significant difference. P=0.976 for paired t-test.

Two-way ANOVA was performed for four groups, namely head epidermis, head dermis, hip
epidermis, and hip dermis, to compare the difference of attenuation coefficient among three
different skin types. The results were shown in Table 3. The ANOVA test revealed there is no
significant variation for attenuation coefficient across age groups and skin types in dermis (Figure
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19B. D). There is a significant difference of attenuation coefficient in epidermis between three
different age groups (Figure 19A, C). For epidermis only, the skin attenuation coefficient increases
with advancing age (Figure 19A, C). And there is a significant variation at head epidermis across
age groups and skin types (Figure 19A). And there is a significant variation of attenuation
coefficient at hip epidermis across age groups, but not skin types (Figure 19C).
Furthermore, the Post Hoc test revealed that there is no difference in attenuation coefficient
between skin type I & II, and III & IV (Figure 19A, red and blue line), the attenuation coefficient
in skin type V & VI is significantly different from the other two skin types as shown in Figure 19A
(green line). And the skin type V & VI have a lower attenuation coefficient than the other skin
types.
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Epidermis
Head
Dermis

Epidermis
Hip
Dermis

Source

df

Mean Square

F

P-value

Skin type

2

.000

3.655

0.03

Age group

2

.000

8.158

0.001

Total

100

Skin type

2

4.562E-7

.695

0.501

Age group

2

5.205E-7

.794

0.455

Total

100

Skin type

2

7.461E-5

1.613

0.205

Age group

2

.000

3.452

0.036

Total

100

Skin type

2

2.967E-7

1.083

0.343

Age group

2

4.125E-7

1.506

0.227

Total

100

Table 3. Two-way ANOVA for three different age groups and skin types. P < 0.05
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Figure 19. The mean attenuation coefficient of forehead and hip skin of different age groups
and skin types. (A) head epidermis, (B) head dermis, (C) hip epidermis, (D) hip dermis. The
error bars indicate 95% confidence interval. P < 0.05

5.4 Discussion
The light transport through skin is determined both by the scattering effects of fibrous
proteins such as collagen, and by the absorbing effects of chromophores such as melanin and
hemoglobin [219, 234, 235]. The attenuation coefficient is an optical property of biological tissue
that indicates how quickly the OCT signal intensity drops over depth.
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We compared the attenuation coefficient of the skin from the forehead and lateral hip since
these areas represent photo-exposed and photo-protected skin, respectively [236]. We observed a
significant difference in the attenuation coefficient comparing epidermis and dermis for all groups
(Figure 18A, B). Regardless of the age differences, we noticed that there was no significant
difference of attenuation coefficient between the forehead and hip (Figure 18C, D).
First, this is because the structure of the epidermis and dermis are quite different, with the
epidermis composed of a structured layering of keratinocytes and the dermis composed of larger
collagen and elastin fibers. The arrangement, size, and shape of these structures results in different
interactions with light and results in different attenuation coefficients.
Furthermore, the absorption of the light in epidermis is mainly caused by the melanin in
melanosomes in epidermis. The amount of melanin is about 10 times higher in darkly pigmented
skin (skin type V and VI) than light pigmented skin (skin type I and II) [237, 238]. Unlike
epidermis, dermis is perfused with blood. Hence, the absorption of the light in dermis is mainly
caused by the hemoglobin in blood [239, 240]. The absorption coefficient of melanin is much
higher than that of hemoglobin [241-243]. This explains that the epidermis has much higher
attenuation coefficient than the dermis as we shown in Figure 18. Campbell et al. also showed that
epidermis has higher attenuation coefficient than the dermis using 3D Monte Carlo modelling
[244].
As light penetrates a turbid medium like skin, multiple scattering events take place. The OCT
system uses a super luminescent diode as a light source with 1305 nm central wavelength. As light
penetrates deeper, it gradually loses spatial coherence because of the scattering of different cellular
structures such as cellular organelles or collagen fiber [245, 246]. The size of cellular organelles
is less than the wavelength of light, which causes the Rayleigh scattering of light [247, 248].
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Whereas the size of collagen fiber is greater than the wavelength of light, causing the Mie
scattering of the light [249]. The scattering behavior of skin is accounted for by the combination
of Rayleigh and Mie scattering [250]. However, the scattering behavior is dominated by Mie
scattering from collagen fibers above 650 nm [251].
In the epidermis, increasing age was associated with a significant increase in the attenuation
coefficient. As age increases, the skin becomes more dehydrated, and the amount of collagen and
elastin will decrease in dermis [252]. Moreover, UV exposure begins to damage the structural
integrity of skin [253]. Skin cell renewal process starts to slow down. The skin appears thinner due
to the dehydration and loss of lipids barrier. Studies have shown that dehydration causes scattering
particles like collagen and organelles to become more densely packed and reduces scattering in
soft tissue [254-256]. Therefore, the OCT signal intensity dropped quickly in the aged group, and
the aged group has a higher attenuation coefficient.
In evaluating the dermis, we found no significant difference in the attenuation coefficient
across age groups and skin types. There are changes seen in the dermis with both aging and chronic
sun exposure. It is possible that these changes do not result in a detectable change in attenuation
coefficient in the dermis. Alternatively, our sample size may have been too small to detect a change.
The color of skin is influenced by several factors: such as melanin, carotene, and hemoglobin.
The amount of melanin varied in different skin types. Melanin is produced by specialized skin
cells called melanocytes in the lower layers of the epidermis and is contained inside a melanosome.
The melanin is transferred into the keratinocytes via a cellular vesicle called a melanosome. As
shown in Figure 19 A and C, dark skin has lower attenuation coefficient. This is more likely due
to the melanosome being evenly distributed, whereas in light skin the melanosome forms clumps
[257]. The clumps of melanosomes will increase the random scattering events of light. But in dark
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skin, without the melanosome clumps, the light can propagate in forward direction. Moreover,
since the dark skin has more compact structure, the intensity changes on OCT images appear not
dramatic compared to the light skin [258].Therefore, the dark skin has lower attenuation coefficient.
In addition, there are differences of attenuation coefficient between light skin and dark skin
only at head epidermis not hip epidermis (Figure 19 A and C). This might indicate sun exposure
has some effect on skin, compared to sun protected regions.
5.5 Conclusion
Tissue attenuation coefficient is a quantitative measure that has been used in evaluating the
health status of tissue in the literature. It is affected by the amount of pigmentation in different
races, as well as the changes in collagen fibers in the aged. The attenuation coefficient increased
with aging. Furthermore, it was observed that darker skins have a lower attenuation coefficient,
especially in the epidermis.
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Chapter 6 CONCLUSIONS AND FUTURE DIRECTIONS
6.1 Conclusions
These studies presented here sought to explore some advanced applications for OCT in
dermatology. We introduced the application of OCT in four different directions: first, we explored
the feasibility of OCT imaging for assisting real-time visualization in skin biopsy; second, we
investigated the concept of contrast-enhanced OCT for melanoma detection in an in vitro study;
third, we tested the capability of monitoring the topical delivery of nanoparticles using OCT; and
finally, we looked into extracting quantitative information such as skin optical properties from
OCT images.
In chapter 2, we showed that a needle insertion in mouse skin can be monitored using OCT
in real-time. The structure of skin and the movement of needle can be clearly seen on the OCT
images without any time delay during the procedures. Next, we proved that using the OCT imaging
is a reliable technique to delineate the margin of lesion in a test phantom. And it is possible to
perform the punch biopsy using OCT hand-held probe attached to a piercing tip,
In chapter 3, we tested the performance of contrast-enhanced OCT in differentiating
melanoma cells from non-melanoma cells in an in vitro study. In this initial study, we showed that
the contrast-agent, Gal3-USGNPs, can differentiate B16 melanoma cells and normal skin
keratinocytes in vitro.
In chapter 4, we proved that OCT can be used to monitor the topical delivery of nanoparticles
on pig skin over time. And the diffusion and penetration of nanoparticles in skin can be improved
by applying chemical and physical enhancers such as DMSO and sonophoresis.
In chapter 5, we proved that quantitative information such as skin attenuation coefficient can
be extracted from OCT images. We measured and compared the skin attenuation coefficient in the
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skin of forehead and lateral hip, the skin of three different age groups, and the skin of three different
Fitzpatrick types. The results showed that epidermis has much higher attenuation coefficient than
dermis. And the skin type V & VI have a lower attenuation coefficient than the other skin types.
6.2 Limitations and Future directions
As a fast, safe, and inexpensive imaging, OCT has not been widely adopted by
dermatologists. The main challenges are, first, the OCT radiomic features for many skin diseases
are still unclear; second, there are no consensus guidelines for diagnosis of skin diseases using
OCT; third, it requires extensive training for the clinicians to interpret the information.
Although OCT could not be used as a robust imaging technique for melanoma diagnosis for
now, the work described in chapter 3 proposed a potential future direction by using contrast agents
to enhance the specificity and sensitivity of OCT imaging. More research is needed to understand
the optimal dosage of contrast agents and their incubation time for in vivo applications in the future.
Moreover, melanoma biomarkers are a limitation for melanoma diagnosis. Currently, there are no
biomarkers that have 100% specificity and sensitivity for melanoma. Future directions may include
biomarkers discovery and validation using large cohorts across multi-centers, and analyze
combinations of multiple putative markers to identify specific prognostic footprints. In addition,
to fully understand the topical delivery of contrast agent, the uptake kinetics of contrast agent
through skin should be investigated in future.
Imaging depth is another limitation for OCT. This is due to the limited penetration of light
in a turbid media like skin tissue. The penetration depth for the OCT system from VivoSight is 1
to 2 mm, which is sufficient to image the whole epidermis (0.077 to 0.267 mm) and the shallow
layer of dermis. However, the thickness of the dermis ranges from 2.1 to 5.9 mm. And as we
mentioned in chapter 1, the Stage 3 melanoma will grow vertically into the deeper layers of dermis.
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Hence, it is crucial that the imaging system has a higher penetration depth to cover the whole
thickness of the dermis. Therefore, to improve the imaging depth, a dual-modality system
combining OCT and high frequency ultrasound could be one of the future research directions.
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APPENDIX: PRINCIPLES OF OPTICAL COHERENCE TOMOGRAPHY
1. Swept-Source OCT
As illustrated in Figure 1, the light from low coherence source is split evenly into sample
arm and reference arm. The backscattered light from the sample mixes and interferes with the
returning light from the reference arm in the fiber coupler. Then the interference signal is detected
by a photodetector and processed to generate depth-scans called A-scans.
A swept-source OCT (SS-OCT) is used in this research work. The SS-OCT uses a spectral
interferometric method that relates the spectral interference signal with the depth profile by Fourier
transform [259, 260]. Without moving the reference mirror, the spectral interference signal, ID(k),
is generated as a function of wavenumber k to reconstruct the sample reflectivity profile (A-scan).
The recorded A-line intensity collected by the detector is proportional to the modulus-squared time
average of the sum of the reference electric field, er, and backscattered electric field es(zm) of each
reflector m at depth z in the sample [176, 261].
∗

𝐼𝐷 (𝑘) = 𝜂[(𝑒𝑟 + 𝑒𝑠 (𝑧𝑚 ))(𝑒𝑟 + 𝑒𝑠 (𝑧𝑚 )) ] = 𝜂[𝑒𝑟 𝑒𝑟∗ + 𝑒𝑟 𝑒𝑠∗ + 𝑒𝑟∗ 𝑒𝑠 + 𝑒𝑠 𝑒𝑠∗ ]

(1.1)

where, η is the detector responsivity.
The amplitudes of electric fields for reference and sample arms were written as:
𝑒𝑟 (𝑘) =

𝑆(𝑘)
√2

𝑟𝑟 𝑒 𝑗2𝑘𝑧𝑟 , and 𝑒𝑠 (𝑘, 𝑧𝑚 ) =

𝑆(𝑘)
√2

𝑗2𝑘𝑧𝑚
∑𝑀
𝑚=1 𝑟𝑚 𝑒

where, S(k) is the spectral density of the light source, rr is the electric field reflectivity of the
reference mirror, rm is the electric field reflectivity of reflector m in sample, and M is the total
number of reflectors along depth z in sample.
Equation 1.1 can be simplified into
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𝐼𝐷 (𝑘) = 𝜂

𝑆(𝑘)
4

[(𝑅𝑟 + ∑𝑀
𝑚=1 𝑅𝑚 )

“Continuous term (DC)”

+2 ∑𝑀
𝑚=1 √𝑅𝑟 𝑅𝑚 cos(2𝑘(𝑧𝑟 − 𝑧𝑚 ))

“Cross-correlation term”

+ ∑𝑀
𝑚≠𝑝=1 √𝑅𝑚 𝑅𝑝 cos (2𝑘(𝑧𝑚 − 𝑧𝑝 ))]

“Auto-correlation term”

where, p is a reflector in sample that is different from reflector m, zp is the position of reflector p
in sample, Rr is the power reflectivity of the reference mirror, and Rm and Rp are the power
reflectivity of reflector m and p in sample.
The continuous term is an optical pathlength-independent offset to detector current. The
cross-correlation term is the desired interferometric signal of OCT images, which is proportional
to the square root of power reflectivity of the reference mirror and each reflector. The autocorrelation term is the interference signal between different reflectors that brings noise and artifacts.
2. Axial and Lateral Resolution in OCT System
An A-scan represents the reflectivity profile of the sample over depth at a fixed lateral
position. And the axial resolution of OCT imaging system, also known as round trip coherence
length, lc, is defined as,

𝑙𝑐 =

2ln (2) 𝜆20
𝜋 Δ𝜆

where, 𝜆0 is the central wavelength of the incident light source, Δ𝜆 is the wavelength bandwidth.
Multiple A-scans are acquired by scanning the light exiting the sample fiber in lateral
direction. The cross-sectional B-scans are formed by assembling the A-scans into a twodimensional image. And the lateral resolution, δx, is defined as,
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𝛿𝑥 = 0.37

𝜆0
𝑁𝐴

where, 𝜆0 is the central wavelength of the incident light source, NA is the numerical aperture of
the objective lens inside the optical probe.
3. Error Rate in OCT
Holmes et. al. measured the FWHM spot diameter of the OCT system in air. The measured
FWHM was 9.6 µm in air, while the calculated theoretical value is 8.4 µm, which gives us a 12.5%
error rate [262]. The error rate in OCT imaging needs to be considered and compensated in future
clinical applications to ensure high accuracy during the dermatological procedures and
measurements.

70

REFERENCES
1.

Brezinski, M.E., Optical Coherence Tomography: Principles and Applications. 2006:
Elsevier Science.

2.

Welzel, J., et al., Optical coherence tomography of the human skin. Journal of the
American Academy of Dermatology, 1997. 37(6): p. 958-963.

3.

Pierce, M.C., et al., Advances in optical coherence tomography imaging for dermatology.
Journal of investigative dermatology, 2004. 123(3): p. 458-63.

4.

Fujimoto, J.G., Optical coherence tomography for ultrahigh resolution in vivo imaging.
Nature biotechnology, 2003. 21(11): p. 1361.

5.

Shishkov, M., B.E. Bouma, and G.J. Tearney, System and method for optical coherence
imaging. 2008, Google Patents.

6.

Cao, T. and H.L. Tey, High‐definition optical coherence tomography–an aid to clinical
practice and research in dermatology. JDDG: Journal der Deutschen Dermatologischen
Gesellschaft, 2015. 13(9): p. 886-890.

7.

Holmes, J. and J. Welzel, OCT in Dermatology. Optical Coherence Tomography:
Technology and Applications, 2015: p. 2189-2207.

8.

Themstrup, L., et al., Optical coherence tomography imaging of non-melanoma skin
cancer undergoing photodynamic therapy reveals subclinical residual lesions.
Photodiagnosis and photodynamic therapy, 2014. 11(1): p. 7-12.

9.

Maier, T., et al., Actinic keratosis in the en‐face and slice imaging mode of high‐definition
optical coherence tomography and comparison with histology. British Journal of
Dermatology, 2013. 168(1): p. 120-128.

71

10.

Themstrup, L., et al., Cryosurgery treatment of actinic keratoses monitored by optical
coherence tomography: a pilot study. Dermatology, 2012. 225(3): p. 242-247.

11.

Gambichler, T., et al., Histopathological correlates of basal cell carcinoma in the slice and
en face imaging modes of high‐definition optical coherence tomography. British Journal of
Dermatology, 2014. 170(6): p. 1358-1361.

12.

Boone, M.A., et al., Imaging of basal cell carcinoma by high‐definition optical coherence
tomography: histomorphological correlation. A pilot study. British journal of dermatology,
2012. 167(4): p. 856-864.

13.

Gambichler, T., et al., In vivo optical coherence tomography of basal cell carcinoma.
Journal of dermatological science, 2007. 45(3): p. 167-173.

14.

Olmedo, J.M., et al., Correlation of thickness of basal cell carcinoma by optical coherence
tomography in vivo and routine histologic findings: a pilot study. Dermatologic surgery,
2007. 33(4): p. 421-426.

15.

Alawi, S.A., et al., Optical coherence tomography for presurgical margin assessment of
non‐melanoma skin cancer–a practical approach. Experimental dermatology, 2013. 22(8):
p. 547-551.

16.

Olsen, J., J. Holmes, and G.B. Jemec, Advances in optical coherence tomography in
dermatology—a review. Journal of biomedical optics, 2018. 23(4): p. 040901.

17.

Israelsen, N.M., et al., The value of ultrahigh resolution OCT in dermatology - delineating
the dermo-epidermal junction, capillaries in the dermal papillae and vellus hairs.
Biomedical optics express, 2018. 9(5): p. 2240-2265.

72

18.

Oltulu, P., et al., Measurement of epidermis, dermis, and total skin thicknesses from six
different body regions with a new ethical histometric technique. Turkish Journal of Plastic
Surgery, 2018. 26(2): p. 56.

19.

Wysocki, A.B., Skin anatomy, physiology, and pathophysiology. The Nursing Clinics of
North America, 1999. 34(4): p. 777-97, v.

20.

Montagna, W., The structure and function of skin. 2012: Elsevier.

21.

Cokkinides, V., et al., American cancer society: Cancer facts and figures. American
Cancer Society, 2005.

22.

Karimkhani, C., et al., The global burden of melanoma: results from the Global Burden of
Disease Study 2015. Br J Dermatol, 2017. 177(1): p. 134-140.

23.

Olbryt, M., Molecular background of skin melanoma development and progression:
therapeutic implications. Postepy Dermatol Alergol, 2019. 36(2): p. 129-138.

24.

Smith, A.P., K. Hoek, and D. Becker, Whole-genome expression profiling of the melanoma
progression pathway reveals marked molecular differences between nevi/melanoma in situ
and advanced-stage melanomas. Cancer biology & therapy, 2005. 4(9): p. 1018-29.

25.

Welch, D.R. and S.F. Goldberg, Molecular mechanisms controlling human melanoma
progression and metastasis. Pathobiology, 1997. 65(6): p. 311-30.

26.

Berger, M.F. and L.A. Garraway, Applications of genomics in melanoma oncogene
discovery. Hematology/Oncology Clinics, 2009. 23(3): p. 397-414.

27.

Sulaimon, S.S. and B.E. Kitchell, The basic biology of malignant melanoma: molecular
mechanisms of disease progression and comparative aspects. J Vet Intern Med, 2003.
17(6): p. 760-72.

73

28.

Miller, A.J. and M.C. Mihm Jr, Melanoma. New England Journal of Medicine, 2006.
355(1): p. 51-65.

29.

Rother, J. and D. Jones, Molecular markers of tumor progression in melanoma. Curr
Genomics, 2009. 10(4): p. 231-9.

30.

Ryu, B., et al., Comprehensive expression profiling of tumor cell lines identifies molecular
signatures of melanoma progression. PLoS One, 2007. 2(7): p. e594.

31.

Meier, F., et al., Molecular events in melanoma development and progression. Front Biosci,
1998. 3: p. D1005-10.

32.

Black, D. and L. Brockway-Lunardi, The melanoma research alliance: the power of patient
advocacy to accelerate research and novel therapies. Cancer immunology research, 2013.
1(6): p. 357-361.

33.

Balch, C.M., et al., Prognostic factors analysis of 17,600 melanoma patients: validation of
the American Joint Committee on Cancer melanoma staging system. Journal of clinical
oncology, 2001. 19(16): p. 3622-3634.

34.

Bichakjian, C.K., et al., Guidelines of care for the management of primary cutaneous
melanoma. Journal of the American Academy of Dermatology, 2011. 65(5): p. 1032-1047.

35.

Domingues, B., et al., Melanoma treatment in review. ImmunoTargets and therapy, 2018.
7: p. 35.

36.

Volkovova, K., et al., Associations between environmental factors and incidence of
cutaneous melanoma. Review. Environmental Health, 2012. 11(1): p. 1-13.

37.

Lin, M.J., et al., Diagnostic accuracy of malignant melanoma according to subtype.
Australasian Journal of Dermatology, 2014. 55(1): p. 35-42.

74

38.

Garbe, C., et al., Systematic review of medical treatment in melanoma: current status and
future prospects. The oncologist, 2011. 16(1): p. 5-24.

39.

Mocellin, S., et al., The Prognostic Value of Circulating Tumor Cells in Patients with
Melanoma: A Systematic Review and Meta-analysis. Clinical Cancer Research, 2006.
12(15): p. 4605.

40.

Rigel, D.S., J. Russak, and R. Friedman, The evolution of melanoma diagnosis: 25 years
beyond the ABCDs. CA: a cancer journal for clinicians, 2010. 60(5): p. 301-316.

41.

Terushkin, V. and A.C. Halpern, Melanoma early detection. Hematology/Oncology
Clinics, 2009. 23(3): p. 481-500.

42.

Ebell, M., Clinical diagnosis of melanoma. Am Fam Physician, 2008. 78(10): p. 1205,
1208.

43.

Bränström, R., et al., Laypersons' perceptual discrimination of pigmented skin lesions.
Journal of the American Academy of Dermatology, 2002. 46(5): p. 667-673.

44.

Thomas, L., et al., Semiological value of ABCDE criteria in the diagnosis of cutaneous
pigmented tumors. Dermatology, 1998. 197(1): p. 11-17.

45.

Brinster, N.K., et al., Dermatopathology: A Volume in the High Yield Pathology Series.
2011: Elsevier Health Sciences.

46.

Lever, W.F., Histopathology of the Skin. Histopathology of the skin., 1949.

47.

Mohammadpour, A., et al., Melanoma: Where we are and where we go. J Cell Physiol,
2019. 234(4): p. 3307-3320.

48.

Levine, D. and D.E. Fisher, Current status of diagnostic and prognostic markers in
melanoma, in Molecular Diagnostics for Melanoma. 2014, Springer. p. 177-197.

75

49.

Nazarian, R.M., et al., Melanoma biomarker expression in melanocytic tumor progression:
a tissue microarray study. Journal of cutaneous pathology, 2010. 37: p. 41-47.

50.

Becker, D., et al., Markers and Tissue Resources for Melanoma: Meeting Report. Cancer
Research, 2006. 66(22): p. 10652.

51.

Zaenker, P. and M.R. Ziman, Serologic autoantibodies as diagnostic cancer biomarkers—
a review. Cancer Epidemiology Prevention Biomarkers, 2013. 22(12): p. 2161-2181.

52.

Balch, C.M., et al., Final version of 2009 AJCC melanoma staging and classification.
Journal of clinical oncology, 2009. 27(36): p. 6199.

53.

Agarwala, S.S., et al., LDH correlation with survival in advanced melanoma from two
large, randomised trials (Oblimersen GM301 and EORTC 18951). European Journal of
Cancer, 2009. 45(10): p. 1807-1814.

54.

Long, G.V., et al., Factors predictive of response, disease progression, and overall survival
after dabrafenib and trametinib combination treatment: a pooled analysis of individual
patient data from randomised trials. The lancet oncology, 2016. 17(12): p. 1743-1754.

55.

Diem, S., et al., Prognostic score for patients with advanced melanoma treated with
ipilimumab. European Journal of Cancer, 2015. 51(18): p. 2785-2791.

56.

Mocellin, S., G. Zavagno, and D. Nitti, The prognostic value of serum S100B in patients
with cutaneous melanoma: A meta‐analysis. International journal of cancer, 2008. 123(10):
p. 2370-2376.

57.

Stahlecker, J., et al., MIA as a reliable tumor marker in the serum of patients with
malignant melanoma. Anticancer research, 2000. 20(6D): p. 5041-5044.

76

58.

Yuan, J., et al., Pretreatment serum VEGF is associated with clinical response and overall
survival in advanced melanoma patients treated with ipilimumab. Cancer immunology
research, 2014. 2(2): p. 127-132.

59.

Wilmott, J.S., et al., Dynamics of chemokine, cytokine, and growth factor serum levels in
BRAF-mutant melanoma patients during BRAF inhibitor treatment. The Journal of
Immunology, 2014. 192(5): p. 2505-2513.

60.

Friedman, E.B., et al., Serum microRNAs as biomarkers for recurrence in melanoma.
Journal of translational medicine, 2012. 10(1): p. 1-10.

61.

Pfeffer, S.R., et al., Detection of exosomal miRNAs in the plasma of melanoma patients.
Journal of clinical medicine, 2015. 4(12): p. 2012-2027.

62.

Khaitan, D., et al., The melanoma‐upregulated long noncoding RNA SPRY4-IT1 modulates
apoptosis and invasion. Cancer research, 2011. 71(11): p. 3852-3862.

63.

Li, R., et al., Long non-coding RNA BANCR promotes proliferation in malignant melanoma
by regulating MAPK pathway activation. PloS one, 2014. 9(6): p. e100893.

64.

Cantile, M., et al., HOTAIR role in melanoma progression and its identification in the
blood of patients with advanced disease. Journal of cellular physiology, 2017. 232(12): p.
3422-3432.

65.

Chen, X., et al., Long non-coding RNA UCA1 targets miR-185-5p and regulates cell
mobility by affecting epithelial-mesenchymal transition in melanoma via Wnt/β-catenin
signaling pathway. Gene, 2018. 676: p. 298-305.

66.

Tian, Y., et al., Potential roles of abnormally expressed long noncoding RNA UCA1 and
Malat-1 in metastasis of melanoma. Melanoma research, 2014. 24(4): p. 335-341.

77

67.

Hida, T., et al., Circulating melanoma cells as a potential biomarker to detect metastasis
and evaluate prognosis. Australasian Journal of Dermatology, 2016. 57(2): p. 145-149.

68.

Palmieri, G., et al., Prognostic value of circulating melanoma cells detected by reverse
transcriptase–polymerase chain reaction. Journal of clinical oncology, 2003. 21(5): p.
767-773.

69.

Karakousis, G., R. Yang, and X. Xu, Circulating melanoma cells as a predictive biomarker.
Journal of Investigative Dermatology, 2013. 133(6): p. 1460-1462.

70.

Mumford, B.S. and G.P. Robertson, Circulating melanoma cells in the diagnosis and
monitoring of melanoma: an appraisal of clinical potential. Molecular diagnosis & therapy,
2014. 18(2): p. 175-183.

71.

Arechederra, M., M.A. Ávila, and C. Berasain, Liquid biopsy for cancer management: a
revolutionary but still limited new tool for precision medicine. Advances in Laboratory
Medicine / Avances en Medicina de Laboratorio, 2020. 1(3).

72.

Buscail, E., et al., High clinical value of liquid biopsy to detect circulating tumor cells and
tumor exosomes in pancreatic ductal adenocarcinoma patients eligible for up-front
surgery. Cancers, 2019. 11(11): p. 1656.

73.

Cohen, J.D., et al., Detection and localization of surgically resectable cancers with a multianalyte blood test. Science, 2018. 359(6378): p. 926-930.

74.

Carli, P., et al., Improvement of malignant/benign ratio in excised melanocytic lesions in
the ‘dermoscopy era’: a retrospective study 1997–2001. British Journal of Dermatology,
2004. 150(4): p. 687-692.

78

75.

Hansen, C., et al., How good are skin cancer clinics at melanoma detection? Number
needed to treat variability across a national clinic group in Australia. Journal of the
American Academy of Dermatology, 2009. 61(4): p. 599-604.

76.

Zhao, M., et al., Detection and Longitudinal Tracking of Pigmented Skin Lesions in 3D
Total-Body Skin Textured Meshes. arXiv preprint arXiv:2105.00374, 2021.

77.

Feit, N.E., S.W. Dusza, and A.A. Marghoob, Melanomas detected with the aid of total
cutaneous photography. British Journal of Dermatology, 2004. 150(4): p. 706-714.

78.

Girardi, S., et al., Superiority of a cognitive education with photographs over ABCD
criteria in the education of the general population to the early detection of melanoma: a
randomized study. International journal of cancer, 2006. 118(9): p. 2276-2280.

79.

Kelly, J.W., et al., A high incidence of melanoma found in patients with multiple dysplastic
naevi by photographic surveillance. Medical journal of Australia, 1997. 167(4): p. 191194.

80.

Kittler, H. and M. Binder, Risks and benefits of sequential imaging of melanocytic skin
lesions in patients with multiple atypical nevi. Archives of dermatology, 2001. 137(12): p.
1590-1595.

81.

Kittler, H., et al., Diagnostic accuracy of dermoscopy. The lancet oncology, 2002. 3(3): p.
159-165.

82.

Braun, R.P., et al., Dermoscopy: what's new? Clinics in Dermatology, 2009. 27(1): p. 2634.

83.

Russo, T., et al., Dermoscopy of malignant skin tumours: what's new? Dermatology, 2017.
233(1): p. 64-73.

79

84.

Braun, R.P., et al., Dermoscopy of pigmented skin lesions. Journal of the American
Academy of Dermatology, 2005. 52(1): p. 109-121.

85.

Nachbar, F., et al., The ABCD rule of dermatoscopy: high prospective value in the
diagnosis of doubtful melanocytic skin lesions. Journal of the American Academy of
Dermatology, 1994. 30(4): p. 551-559.

86.

Vestergaard, M., et al., Dermoscopy compared with naked eye examination for the
diagnosis of primary melanoma: a meta‐analysis of studies performed in a clinical setting.
British Journal of Dermatology, 2008. 159(3): p. 669-676.

87.

Bafounta, M.-L., et al., Is dermoscopy (epiluminescence microscopy) useful for the
diagnosis of melanoma?: Results of a meta-analysis using techniques adapted to the
evaluation of diagnostic tests. Archives of dermatology, 2001. 137(10): p. 1343-1350.

88.

Menzies, S.W., et al., Frequency and morphologic characteristics of invasive melanomas
lacking specific surface microscopic features. Archives of Dermatology, 1996. 132(10): p.
1178-1182.

89.

Argenziano, G., et al., Dermoscopy of pigmented skin lesions: results of a consensus
meeting via the Internet. Journal of the American Academy of Dermatology, 2003. 48(5):
p. 679-693.

90.

Henning, J.S., et al., The CASH (color, architecture, symmetry, and homogeneity)
algorithm for dermoscopy. Journal of the American Academy of Dermatology, 2007. 56(1):
p. 45-52.

91.

Argenziano, G., et al., Epiluminescence microscopy for the diagnosis of doubtful
melanocytic skin lesions: comparison of the ABCD rule of dermatoscopy and a new 7-point
checklist based on pattern analysis. Archives of dermatology, 1998. 134(12): p. 1563-1570.

80

92.

Psaty, E.L. and A.C. Halpern, Current and emerging technologies in melanoma diagnosis:
the state of the art. Clinics in Dermatology, 2009. 27(1): p. 35-45.

93.

Gerger, A., et al., In vivo confocal laser scanning microscopy of melanocytic skin tumours:
diagnostic applicability using unselected tumour images. British Journal of Dermatology,
2008. 158(2): p. 329-333.

94.

Pellacani, G., A.M. Cesinaro, and S. Seidenari, In vivo assessment of melanocytic nests in
nevi and melanomas by reflectance confocal microscopy. Modern pathology, 2005. 18(4):
p. 469-474.

95.

Pellacani, G., A.M. Cesinaro, and S. Seidenari, Reflectance-mode confocal microscopy of
pigmented skin lesions–improvement in melanoma diagnostic specificity. Journal of the
American Academy of Dermatology, 2005. 53(6): p. 979-985.

96.

Pellacani, G., et al., The impact of in vivo reflectance confocal microscopy for the
diagnostic accuracy of melanoma and equivocal melanocytic lesions. Journal of
investigative dermatology, 2007. 127(12): p. 2759-2765.

97.

Claxton, N.S., T.J. Fellers, and M.W. Davidson, Laser scanning confocal microscopy.
Encyclopedia of Medical Devices and Instrumentation, 2006. 21: p. 1-37.

98.

Ilie, M.A., et al., Current and future applications of confocal laser scanning microscopy
imaging in skin oncology. Oncology letters, 2019. 17(5): p. 4102-4111.

99.

ULRICH, J. and V. Christiane, Ultrasound in dermatology. Part II. Ultrasound of regional
lymph node basins and subcutaneous tumours. European Journal of Dermatology, 2001.
11(1): p. 73-9.

100.

Schmid-Wendtner, M.-H. and W. Burgdorf, Ultrasound scanning in dermatology.
Archives of dermatology, 2005. 141(2): p. 217-224.

81

101.

Smith, L. and S. MacNeil, State of the art in non-invasive imaging of cutaneous melanoma.
Skin Research and Technology, 2011. 17(3): p. 257-269.

102.

Machet, L., et al., Preoperative measurement of thickness of cutaneous melanoma using
high-resolution 20 MHz ultrasound imaging: A monocenter prospective study and
systematic review of the literature. Ultrasound in medicine & biology, 2009. 35(9): p.
1411-1420.

103.

Lassau, N., et al., Prognostic value of high-frequency sonography and color Doppler
sonography for the preoperative assessment of melanomas. AJR. American journal of
roentgenology, 1999. 172(2): p. 457-461.

104.

Hoffmann, K., et al., Malignant melanoma in 20-MHz B scan sonography. Dermatology,
1992. 185(1): p. 49-55.

105.

Gassenmaier, G., et al., Value of high resolution ultrasound in determination of vertical
tumor thickness in malignant melanoma of the skin. Der Hautarzt; Zeitschrift fur
Dermatologie, Venerologie, und verwandte Gebiete, 1990. 41(7): p. 360-364.

106.

Gambichler, T., et al., Preoperative ultrasonic assessment of thin melanocytic skin lesions
using a 100‐MHz ultrasound transducer: a comparative study. Dermatologic surgery, 2007.
33(7): p. 818-824.

107.

Foster, P.J., et al., Cellular magnetic resonance imaging: in vivo imaging of melanoma
cells in lymph nodes of mice. Neoplasia, 2008. 10(3): p. 207-216.

108.

Belhocine, T.Z., et al., Role of nuclear medicine in the management of cutaneous malignant
melanoma. Journal of Nuclear Medicine, 2006. 47(6): p. 957-967.

109.

Santos, I.P., et al., Improving clinical diagnosis of early-stage cutaneous melanoma based
on Raman spectroscopy. British journal of cancer, 2018. 119(11): p. 1339-1346.

82

110.

Oh, J.-T., et al., Three-dimensional imaging of skin melanoma in vivo by dual-wavelength
photoacoustic microscopy. Journal of biomedical optics, 2006. 11(3): p. 034032.

111.

Dinnes, J., et al., Ultrasound, CT, MRI, or PET‐CT for staging and re‐staging of adults
with cutaneous melanoma. Cochrane Database of Systematic Reviews, 2019(7).

112.

Zhang, H.F., et al., Functional photoacoustic microscopy for high-resolution and
noninvasive in vivo imaging. Nature biotechnology, 2006. 24(7): p. 848-851.

113.

Schmitt, J., M. Yadlowsky, and R. Bonner, Subsurface imaging of living skin with optical
coherence microscopy. Dermatology, 1995. 191(2): p. 93-98.

114.

Welzel, J., Optical coherence tomography in dermatology: a review. Skin Research and
Technology: Review article, 2001. 7(1): p. 1-9.

115. Tsai, T.H., et al., Multiphoton microscopy in dermatological imaging. J Dermatol Sci, 2009.
56(1): p. 1-8.
116.

Mogensen, M., et al., Assessment of optical coherence tomography imaging in the
diagnosis of non‐melanoma skin cancer and benign lesions versus normal skin: observer‐
blinded evaluation by dermatologists and pathologists. Dermatologic Surgery, 2009. 35(6):
p. 965-972.

117.

Jørgensen, T.M., et al., Machine‐learning classification of non‐melanoma skin cancers
from image features obtained by optical coherence tomography. Skin Research and
Technology, 2008. 14(3): p. 364-369.

118.

Boone, M., et al., In vivo assessment of optical properties of basal cell carcinoma and
differentiation of BCC subtypes by high-definition optical coherence tomography.
Biomedical optics express, 2016. 7(6): p. 2269-2284.

83

119.

Pelosini, L., et al., In vivo optical coherence tomography (OCT) in periocular basal cell
carcinoma: correlations between in vivo OCT images and postoperative histology. British
Journal of Ophthalmology, 2013. 97(7): p. 890-894.

120.

Rajabi-Estarabadi, A., et al., Optical coherence tomography imaging of melanoma skin
cancer. Lasers in medical science, 2019. 34(2): p. 411-420.

121.

Goodson, A.G. and D. Grossman, Strategies for early melanoma detection: Approaches to
the patient with nevi. Journal of the American Academy of Dermatology, 2009. 60(5): p.
719-735.

122.

Gambichler, T., et al., High‐definition optical coherence tomography of melanocytic skin
lesions. Journal of biophotonics, 2015. 8(8): p. 681-686.

123.

Boone, M.A., et al., High-definition optical coherence tomography imaging of melanocytic
lesions: a pilot study. Archives of dermatological research, 2014. 306(1): p. 11-26.

124.

Hinz, T., et al., Assessment of tumor thickness in melanocytic skin lesions: comparison of
optical coherence tomography, 20-MHz ultrasound and histopathology. Dermatology,
2011. 223(2): p. 161-168.

125.

Mogensen, M., et al., OCT imaging of skin cancer and other dermatological diseases.
Journal of biophotonics, 2009. 2(6‐7): p. 442-451.

126.

Oliveira, A., et al., Verrucous melanoma simulating melanoacanthoma: dermoscopic,
reflectance confocal microscopic and high-definition optical coherence tomography
presentation of a rare melanoma variant. 2016.

127.

Olsen, J., L. Themstrup, and G. Jemec, Optical coherence tomography in dermatology. G
Ital Dermatol Venereol, 2015. 150(5): p. 603-615.

84

128.

De Carvalho, N., et al., In vivo micro-angiography by means of speckle-variance optical
coherence tomography (SV-OCT) is able to detect microscopic vascular changes in naevus
to melanoma transition. Journal of the European Academy of Dermatology and
Venereology: JEADV, 2015. 30(10): p. e67-e68.

129.

Schuh, S., et al., Imaging blood vessel morphology in skin: dynamic optical coherence
tomography as a novel potential diagnostic tool in dermatology. Dermatology and therapy,
2017. 7(2): p. 187-202.

130.

Blumetti, T.C.M.P., et al., Optical coherence tomography (OCT) features of nevi and
melanomas and their association with intraepidermal or dermal involvement: a pilot study.
Journal of the American Academy of Dermatology, 2015. 73(2): p. 315-317.

131.

Weissleder, R., Molecular imaging in cancer. Science, 2006. 312(5777): p. 1168-1171.

132.

James, M.L. and S.S. Gambhir, A molecular imaging primer: modalities, imaging agents,
and applications. Physiological reviews, 2012. 92(2): p. 897-965.

133.

Weissleder, R. and U. Mahmood, Molecular imaging. Radiology, 2001. 219(2): p. 316333.

134.

Kelloff, G.J., et al., The progress and promise of molecular imaging probes in oncologic
drug development. Clinical Cancer Research, 2005. 11(22): p. 7967-7985.

135.

Willmann, J.K., et al., Molecular imaging in drug development. Nature reviews Drug
discovery, 2008. 7(7): p. 591-607.

136.

Jaffer, F.A. and R. Weissleder, Molecular imaging in the clinical arena. Jama, 2005.
293(7): p. 855-862.

137.

Wallace, A.M., et al., Lymphoseek: a molecular imaging agent for melanoma sentinel
lymph node mapping. Ann Surg Oncol, 2007. 14(2): p. 913-21.

85

138.

Hong, H., J. Sun, and W. Cai, Anatomical and molecular imaging of skin cancer. Clinical,
cosmetic and investigational dermatology, 2008. 1: p. 1-17.

139.

Gambichler, T., et al., Applications of optical coherence tomography in dermatology.
Journal of dermatological science, 2005. 40(2): p. 85-94.

140.

Zuber, T.J., Punch biopsy of the skin. American family physician, 2002. 65(6): p. 1155-8,
1161-2, 1164.

141.

Kollias, N. and G.N. Stamatas, Optical non-invasive approaches to diagnosis of skin
diseases. J Investig Dermatol Symp Proc, 2002. 7(1): p. 64-75.

142.

Gamo, R., A. Pampin, and U. Floristan, Reflectance Confocal Microscopy in Lentigo
Maligna. Actas Dermosifiliogr, 2016. 107(10): p. 830-835.

143.

Kadouch, D., et al., Diagnostic accuracy of confocal microscopy imaging versus punch
biopsy for diagnosing and subtyping basal cell carcinoma. Journal of the European
Academy of Dermatology and Venereology, 2017.

144.

Calzavara-Pinton, P., et al., Reflectance confocal microscopy for in vivo skin imaging.
Photochem Photobiol, 2008. 84(6): p. 1421-30.

145.

Champin, J., et al., In vivo reflectance confocal microscopy to optimize the spaghetti
technique for defining surgical margins of lentigo maligna. Dermatol Surg, 2014. 40(3): p.
247-56.

146.

Longo, C., et al., In Vivo and Ex Vivo Confocal Microscopy for Dermatologic and Mohs
Surgeons. Dermatol Clin, 2016. 34(4): p. 497-504.

147.

Rajadhyaksha, M., et al., Reflectance confocal microscopy of skin in vivo: From bench to
bedside. Lasers Surg Med, 2017. 49(1): p. 7-19.

86

148.

Lin, S.J., S.H. Jee, and C.Y. Dong, Multiphoton microscopy: a new paradigm in
dermatological imaging. Eur J Dermatol, 2007. 17(5): p. 361-6.

149.

Zoumi, A., A. Yeh, and B.J. Tromberg, Imaging cells and extracellular matrix in vivo by
using second-harmonic generation and two-photon excited fluorescence. Proceedings of
the National Academy of Sciences, 2002. 99(17): p. 11014-11019.

150.

Rallan, D. and C.C. Harland, Ultrasound in dermatology--basic principles and
applications. Clin Exp Dermatol, 2003. 28(6): p. 632-8.

151.

Nassiri-Kashani, M., et al., Pre-operative assessment of basal cell carcinoma dimensions
using high frequency ultrasonography and its correlation with histopathology. Skin
Research and Technology, 2013. 19(1): p. E132-E138.

152. Ruocco, E., et al., Noninvasive imaging of skin tumors. Dermatologic surgery, 2004. 30(s2):
p. 301-310.
153.

Mogensen, M. and G.B. Jemec, Diagnosis of nonmelanoma skin cancer/keratinocyte
carcinoma: a review of diagnostic accuracy of nonmelanoma skin cancer diagnostic tests
and technologies. Dermatologic Surgery, 2007. 33(10): p. 1158-1174.

154.

Avanaki, M.R., et al., Quantitative evaluation of scattering in optical coherence
tomography skin images using the extended Huygens-Fresnel theorem. Appl Opt, 2013.
52(8): p. 1574-80.

155.

Avanaki, M.R., et al., Investigation of basal cell carcinoma using dynamic focus optical
coherence tomography. Appl Opt, 2013. 52(10): p. 2116-24.

156.

Good, L.M., M.D. Miller, and W.A. High, Intralesional agents in the management of
cutaneous malignancy: a review. J Am Acad Dermatol, 2011. 64(2): p. 413-22.

87

157.

Hochman, B., et al., Intralesional triamcinolone acetonide for keloid treatment: a
systematic review. Aesthetic Plast Surg, 2008. 32(4): p. 705-9.

158.

Aldahan, A.S., et al., Efficacy of intralesional immunotherapy for the treatment of warts:
A review of the literature. Dermatol Ther, 2016. 29(3): p. 197-207.

159.

Jeneby, T.T., B. Chang, and L.P. Bucky, Ultraviolet-assisted punch biopsy mapping for
lentigo maligna melanoma. Ann Plast Surg, 2001. 46(5): p. 495-9; discussion 499-500.

160.

Chen, C.S., et al., Multimodal in vivo optical imaging, including confocal microscopy,
facilitates presurgical margin mapping for clinically complex lentigo maligna melanoma.
Br J Dermatol, 2005. 153(5): p. 1031-6.

161.

Adabi, S., et al., Universal in vivo textural model for human skin based on optical
coherence tomograms. Scientific reports, 2017. 7(1): p. 17912.

162.

Brown, E.R., et al., Association of galectin-3 expression with melanoma progression and
prognosis. European Journal of Cancer, 2012. 48(6): p. 865-874.

163.

Vereecken, P., et al., Expression of galectin-3 in primary and metastatic melanoma:
immunohistochemical studies on human lesions and nude mice xenograft tumors. Archives
of dermatological research, 2005. 296(8): p. 353-358.

164.

Braeuer, R.R., et al., Galectin-3 contributes to melanoma growth and metastasis via
regulation of NFAT1 and autotaxin. Cancer research, 2012. 72(22): p. 5757-5766.

165.

Wang, Y.-G., et al., Galectin-3 increases the motility of mouse melanoma cells by
regulating matrix metalloproteinase-1 expression. Experimental & molecular medicine,
2012. 44(6): p. 387-393.

166.

Dreaden, E.C., et al., The golden age: gold nanoparticles for biomedicine. Chemical
Society Reviews, 2012. 41(7): p. 2740-2779.

88

167.

Schmid, G., W.G. Kreyling, and U. Simon, Toxic effects and biodistribution of ultrasmall
gold nanoparticles. Arch Toxicol, 2017.

168.

Liu, J., et al., PEGylation and zwitterionization: pros and cons in the renal clearance and
tumor targeting of near-IR-emitting gold nanoparticles. Angew Chem Int Ed Engl, 2013.
52(48): p. 12572-6.

169.

Srinivasan, N., et al., Poly N-acetyllactosamine substitutions on N-and not Ooligosaccharides or Thomsen–Friedenreich antigen facilitate lung specific metastasis of
melanoma cells via galectin-3. Glycoconjugate journal, 2009. 26(4): p. 445-456.

170.

Inohara, H. and A. Raz, Effects of natural complex carbohydrate (citrus pectin) on murine
melanoma cell properties related to galectin-3 functions. Glycoconjugate journal, 1994.
11(6): p. 527-532.

171.

Prieto, V.G., et al., Galectin-3 expression is associated with tumor progression and pattern
of sun exposure in melanoma. Clinical Cancer Research, 2006. 12(22): p. 6709-6715.

172.

Turani, Z., et al., Optical Radiomic Signatures Derived from Optical Coherence
Tomography Images Improve Identification of Melanoma. Cancer Research, 2019. 79(8):
p. 2021.

173.

Pickett, H., Shave and punch biopsy for skin lesions. American family physician, 2011.
84(9): p. 995.

174.

Fujimoto, J.G., et al., Optical coherence tomography: an emerging technology for
biomedical imaging and optical biopsy. Neoplasia, 2000. 2(1-2): p. 9-25.

175.

Huang, D., et al., Optical coherence tomography. Science, 1991. 254(5035): p. 1178-1181.

176.

Fercher, A.F., et al., Optical coherence tomography-principles and applications. Reports
on progress in physics, 2003. 66(2): p. 239.

89

177.

Leitgeb, R., C. Hitzenberger, and A.F. Fercher, Performance of fourier domain vs. time
domain optical coherence tomography. Optics express, 2003. 11(8): p. 889-894.

178.

Lee, T.M., et al., Engineered microsphere contrast agents for optical coherence
tomography. Optics letters, 2003. 28(17): p. 1546-1548.

179.

De Jong, W.H. and P.J. Borm, Drug delivery and nanoparticles: applications and hazards.
International journal of nanomedicine, 2008. 3(2): p. 133.

180.

Cho, K., et al., Therapeutic nanoparticles for drug delivery in cancer. Clinical cancer
research, 2008. 14(5): p. 1310-1316.

181.

Hainfeld, J., et al., Gold nanoparticles: a new X-ray contrast agent. The British journal of
radiology, 2006. 79(939): p. 248-253.

182.

Kim, E.H., et al., Synthesis of ferrofluid with magnetic nanoparticles by sonochemical
method for MRI contrast agent. Journal of Magnetism and Magnetic Materials, 2005. 289:
p. 328-330.

183.

Roy, I., et al., Ceramic-based nanoparticles entrapping water-insoluble photosensitizing
anticancer drugs: A novel drug− carrier system for photodynamic therapy. Journal of the
American Chemical Society, 2003. 125(26): p. 7860-7865.

184.

Chatterjee, D.K., L.S. Fong, and Y. Zhang, Nanoparticles in photodynamic therapy: an
emerging paradigm. Advanced drug delivery reviews, 2008. 60(15): p. 1627-1637.

185.

Daniel, M.-C. and D. Astruc, Gold nanoparticles: assembly, supramolecular chemistry,
quantum-size-related properties, and applications toward biology, catalysis, and
nanotechnology. Chemical reviews, 2004. 104(1): p. 293-346.

186.

Sperling, R.A., et al., Biological applications of gold nanoparticles. Chemical Society
Reviews, 2008. 37(9): p. 1896-1908.

90

187.

Ghosh, P., et al., Gold nanoparticles in delivery applications. Advanced drug delivery
reviews, 2008. 60(11): p. 1307-1315.

188.

Ghosh, S.K. and T. Pal, Interparticle coupling effect on the surface plasmon resonance of
gold nanoparticles: from theory to applications. Chemical reviews, 2007. 107(11): p.
4797-4862.

189.

Dykman, L. and N. Khlebtsov, Gold nanoparticles in biomedical applications: recent
advances and perspectives. Chemical Society Reviews, 2012. 41(6): p. 2256-2282.

190.

Chen, J., et al., Gold nanocages: bioconjugation and their potential use as optical imaging
contrast agents. Nano letters, 2005. 5(3): p. 473-477.

191.

Zhang, Q., et al., Gold nanoparticles as a contrast agent for in vivo tumor imaging with
photoacoustic tomography. Nanotechnology, 2009. 20(39): p. 395102.

192.

Jain, S., D. Hirst, and J. O'sullivan, Gold nanoparticles as novel agents for cancer therapy.
The British journal of radiology, 2012. 85(1010): p. 101-113.

193.

Sokolov, K., et al., Real-time vital optical imaging of precancer using anti-epidermal
growth factor receptor antibodies conjugated to gold nanoparticles. Cancer research, 2003.
63(9): p. 1999-2004.

194.

Leekumjorn, S. and A.K. Sum, Molecular study of the diffusional process of DMSO in
double lipid bilayers. Biochimica et Biophysica Acta (BBA)-Biomembranes, 2006.
1758(11): p. 1751-1758.

195.

Castro, C.A., et al., Behavioral effects of vehicles: DMSO, ethanol, Tween-20, Tween-80,
and emulphor-620. Pharmacology Biochemistry and Behavior, 1995. 50(4): p. 521-526.

91

196.

Pelletier, J.S., et al., Rosacea blepharoconjunctivitis treated with a novel preparation of
dilute povidone iodine and dimethylsulfoxide: a case report and review of the literature.
Ophthalmology and therapy, 2015. 4(2): p. 143-150.

197.

Shinoda, W., Permeability across lipid membranes. Biochimica et Biophysica Acta
(BBA)-Biomembranes, 2016. 1858(10): p. 2254-2265.

198.

Stoughton, R. and W. Fritsch, Influence of dimethylsulfoxide (DMSO): on human
percutaneous absorption. Archives of dermatology, 1964. 90(5): p. 512-517.

199.

Capriotti, K. and J.A. Capriotti, Dimethyl sulfoxide: history, chemistry, and clinical utility
in dermatology. The Journal of clinical and aesthetic dermatology, 2012. 5(9): p. 24.

200.

Smith, N.B., Perspectives on transdermal ultrasound mediated drug delivery. International
journal of nanomedicine, 2007. 2(4): p. 585.

201.

Tezel, A. and S. Mitragotri, Interactions of inertial cavitation bubbles with stratum
corneum lipid bilayers during low-frequency sonophoresis. Biophysical journal, 2003.
85(6): p. 3502-3512.

202.

Mitragotri, S., D. Blankschtein, and R. Langer, Transdermal drug delivery using lowfrequency sonophoresis. Pharmaceutical research, 1996. 13(3): p. 411-420.

203.

Bashkatov, A.N., E.A. Genina, and V.V. Tuchin, Optical properties of skin, subcutaneous,
and muscle tissues: a review. Journal of Innovative Optical Health Sciences, 2011. 4(01):
p. 9-38.

204.

Langer, K., On the anatomy and physiology of the skin: I. The cleavability of the cutis.
British journal of plastic surgery, 1978. 31(1): p. 3-8.

205.

Lui, H., et al., Real-time Raman spectroscopy for in vivo skin cancer diagnosis. Cancer
research, 2012. 72(10): p. 2491-2500.

92

206.

Martin, M.E., et al., Development of an advanced hyperspectral imaging (HSI) system with
applications for cancer detection. Annals of biomedical engineering, 2006. 34(6): p. 10611068.

207.

Yaroslavsky, A.N., V. Neel, and R.R. Anderson, Demarcation of nonmelanoma skin
cancer margins in thick excisions using multispectral polarized light imaging. Journal of
investigative dermatology, 2003. 121(2): p. 259-266.

208.

Gerger, A., et al., Sensitivity and specificity of confocal laser‐scanning microscopy for in
vivo diagnosis of malignant skin tumors. Cancer: Interdisciplinary International Journal of
the American Cancer Society, 2006. 107(1): p. 193-200.

209.

Harland, C., et al., Differentiation of common benign pigmented skin lesions from
melanoma by high‐resolution ultrasound. British Journal of Dermatology, 2000. 143(2): p.
281-289.

210.

Woodward, R.M., et al., Terahertz pulse imaging in reflection geometry of human skin
cancer and skin tissue. Physics in Medicine & Biology, 2002. 47(21): p. 3853.

211.

Mogensen, M., et al. Optical coherence tomography for imaging of skin and skin diseases.
in Seminars in cutaneous medicine and surgery. 2009. WB Saunders.

212.

Zhao, Y., et al., Phase-resolved optical coherence tomography and optical Doppler
tomography for imaging blood flow in human skin with fast scanning speed and high
velocity sensitivity. Optics letters, 2000. 25(2): p. 114-116.

213.

Gladkova, N.D., et al., In vivo optical coherence tomography imaging of human skin: norm
and pathology. Skin Research and Technology, 2000. 6(1): p. 6-16.

214.

Coleman, A.J., et al., Histological correlates of optical coherence tomography in non‐
melanoma skin cancer. Skin Research and Technology, 2013. 19(1): p. e10-e19.

93

215.

Adabi, S., et al., Textural Analysis of Optical Coherence Tomography Skin Images:
quantitative differentiation between healthy and cancerous tissues. PROGRESS IN
BIOMEDICAL OPTICS AND IMAGING, 2017. 10053: p. 100533F.

216.

Adabi, S., et al., Optical Coherence Tomography Technology and Quality Improvement
Methods for Optical Coherence Tomography Images of Skin: A Short Review. Biomed Eng
Comput Biol, 2017. 8: p. 1179597217713475.

217.

Boone, M.A., et al., In vivo assessment of optical properties of melanocytic skin lesions
and differentiation of melanoma from non-malignant lesions by high-definition optical
coherence tomography. Arch Dermatol Res, 2016. 308(1): p. 7-20.

218.

Jacques, S.L., Optical properties of biological tissues: a review. Phys Med Biol, 2013.
58(11): p. R37-61.

219.

Van Gemert, M., et al., Skin optics. IEEE Transactions on biomedical engineering, 1989.
36(12): p. 1146-1154.

220.

Schmitt, J., A. Knüttel, and R. Bonner, Measurement of optical properties of biological
tissues by low-coherence reflectometry. Applied Optics, 1993. 32(30): p. 6032-6042.

221.

Vermeer, K.A., et al., Depth-resolved model-based reconstruction of attenuation
coefficients in optical coherence tomography. Biomed Opt Express, 2013. 5(1): p. 322-37.

222.

Amaral, M.M., et al., General model for depth-resolved estimation of the optical
attenuation coefficients in optical coherence tomography. J Biophotonics, 2019. 12(10): p.
e201800402.

223.

Liu, J., et al., Optimized depth-resolved estimation to measure optical attenuation
coefficients from optical coherence tomography and its application in cerebral damage
determination. J Biomed Opt, 2019. 24(3): p. 1-11.

94

224.

Azuma, S., et al., Pixel-wise segmentation of severely pathologic retinal pigment
epithelium and choroidal stroma using multi-contrast Jones matrix optical coherence
tomography. Biomed Opt Express, 2018. 9(7): p. 2955-2973.

225.

Kasaragod, D., et al., Machine-learning based segmentation of the optic nerve head using
multi-contrast Jones matrix optical coherence tomography with semi-automatic training
dataset generation. Biomed Opt Express, 2018. 9(7): p. 3220-3243.

226.

van der Meer, F.J., et al., Localized measurement of optical attenuation coefficients of
atherosclerotic plaque constituents by quantitative optical coherence tomography. IEEE
Trans Med Imaging, 2005. 24(10): p. 1369-76.

227.

Xu, C., et al., Characterization of atherosclerosis plaques by measuring both
backscattering and attenuation coefficients in optical coherence tomography. Journal of
biomedical optics, 2008. 13(3): p. 034003.

228.

Xu, X., et al., Viscosity monitoring during hemodiluted blood coagulation using optical
coherence elastography. IEEE J Sel Top Quantum Electron, 2019. 25(1).

229.

Hojjatoleslami, A. and M.R. Avanaki, OCT skin image enhancement through attenuation
compensation. Applied optics, 2012. 51(21): p. 4927-4935.

230.

Karsten, A.E. and J.E. Smit, Modeling and verification of melanin concentration on human
skin type. Photochemistry photobiology, 2012. 88(2): p. 469-474.

231.

Wu, S., et al., Optical features for chronological aging and photoaging skin by optical
coherence tomography. Lasers in medical science, 2013. 28(2): p. 445-450.

232.

Sachdeva, S., Fitzpatrick skin typing: Applications in dermatology. Indian Journal of
Dermatology, Venereology, Leprology, 2009. 75(1): p. 93.

95

233.

Chang, S. and A. Bowden, Review of methods and applications of attenuation coefficient
measurements with optical coherence tomography. Journal of biomedical optics, 2019.
24(9): p. 090901.

234.

Simpson, C.R., et al., Near-infrared optical properties of ex vivo human skin and
subcutaneous tissues measured using the Monte Carlo inversion technique. Physics in
Medicine & Biology, 1998. 43(9): p. 2465.

235.

Tuchin, V. Skin optics: modeling of light transport and measuring of optical parameters.
in Medical Optical Tomography: Functional Imaging and Monitoring. 1993. International
Society for Optics and Photonics.

236.

Alaluf, S., et al., Ethnic variation in melanin content and composition in photoexposed and
photoprotected human skin. Pigment Cell Research, 2002. 15(2): p. 112-118.

237.

De Leeuw, S.M., et al., Melanin content of cultured human melanocytes and UV-induced
cytotoxicity. Journal of Photochemistry Photobiology B: Biology, 2001. 61(3): p. 106-113.

238.

Brenner, M. and V. Hearing, The protective role of melanin against UV damage in human
skin. Photochemistry photobiology, 2008. 84(3): p. 539-549.

239.

Yudovsky, D. and L. Pilon, Rapid and accurate estimation of blood saturation, melanin
content, and epidermis thickness from spectral diffuse reflectance. Applied optics, 2010.
49(10): p. 1707-1719.

240.

Swain, I. and L. Grant, Methods of measuring skin blood flow. Physics in Medicine &
Biology, 1989. 34(2): p. 151.

241.

Thompson, C., et al., Melanin granule model for laser-induced thermal damage in the
retina. Bulletin of mathematical biology, 1996. 58(3): p. 513-553.

96

242.

Marchesini, R., et al., Optical properties of in vitro epidermis and their possible
relationship with optical properties of in vivo skin. Journal of Photochemistry
Photobiology B: Biology, 1992. 16(2): p. 127-140.

243.

Wray, S., et al., Characterization of the near infrared absorption spectra of cytochrome
aa3 and haemoglobin for the non-invasive monitoring of cerebral oxygenation. Biochimica
et Biophysica Acta (BBA)-Bioenergetics, 1988. 933(1): p. 184-192.

244.

Campbell, C.L., et al. 3d monte carlo radiation transfer modelling of photodynamic
therapy. in Biophotonics South America. 2015. International Society for Optics and
Photonics.

245.

Schmitt, J.M., et al., Optical-coherence tomography of a dense tissue: statistics of
attenuation and backscattering. Physics in Medicine & Biology, 1994. 39(10): p. 1705.

246.

Tuchin, V.V., Tissue optics and photonics: light-tissue interaction. Journal of Biomedical
Photonics & Engineering, 2015. 1(2).

247.

Saidi, I.S., S.L. Jacques, and F.K. Tittel, Mie and Rayleigh modeling of visible-light
scattering in neonatal skin. Applied optics, 1995. 34(31): p. 7410-7418.

248.

Hahn, D.W., Light scattering theory. Department of Mechanical and Aerospace
Engineering, University of Florida, 2009.

249.

Zonios, G., J. Bykowski, and N. Kollias, Skin melanin, hemoglobin, and light scattering
properties can be quantitatively assessed in vivo using diffuse reflectance spectroscopy.
Journal of Investigative Dermatology, 2001. 117(6): p. 1452-1457.

250.

Zonios, G. and A. Dimou, Light scattering spectroscopy of human skin in vivo. Optics
Express, 2009. 17(3): p. 1256-1267.

97

251.

Jacques, S.L., Origins of tissue optical properties in the UVA, visible, and NIR regions.
OSA TOPS on advances in optical imaging and photon migration, 1996. 2: p. 364-369.

252.

Makrantonaki, E. and C. Zouboulis, Molecular mechanisms of skin aging: state of the art.
Annals of the New York Academy of Sciences, 2007. 1119(1): p. 40-50.

253.

Vierkötter, A. and J. Krutmann, Environmental influences on skin aging and ethnic-specific
manifestations. Dermato-endocrinology, 2012. 4(3): p. 227-231.

254.

Rylander, C.G., et al., Dehydration mechanism of optical clearing in tissue. Journal of
biomedical optics, 2006. 11(4): p. 041117.

255.

Askar'yan, G., Enhancement of transmission of laser and other radiation by soft turbid
physical and biological media. Soviet Journal of Quantum Electronics, 1982. 12(7): p. 877.

256.

Tuchin, V. Tissue Optics: Light Scattering Methods and Instruments for Medical
Diagnosis. 2000.

257.

Murase, D., et al., Autophagy has a significant role in determining skin color by regulating
melanosome degradation in keratinocytes. Journal of Investigative Dermatology, 2013.
133(10): p. 2416-2424.

258.

Richards, G.M., C.O. Oresajo, and R.M. Halder, Structure and function of ethnic skin and
hair. Dermatologic clinics, 2003. 21(4): p. 595-600.

259.

Drexler, W. and J.G. Fujimoto, Optical coherence tomography: technology and
applications. 2008: Springer Science & Business Media.

260.

Wiener, N., Generalized harmonic analysis. Acta mathematica, 1930. 55(1): p. 117-258.

261.

Izatt, J.A. and M.A. Choma, Theory of optical coherence tomography, in Optical
coherence tomography. 2008, Springer. p. 47-72.

98

262.

Holmes, J., et al. Multi-channel Fourier domain OCT system with superior lateral
resolution for biomedical applications. in Coherence domain optical methods and optical
coherence tomography in biomedicine XII. 2008. International Society for Optics and
Photonics.

99

ABSTRACT
THE ADVANCED APPLICATIONS FOR OPTICAL COHERENCE TOMOGRAPHY IN
SKIN IMAGING
by
QIUYUN XU
December 2021
Co-Advisor: Dr. Kamran Avanaki
Co-Advisor: Dr. E Mark Haacke
Major: Biomedical Engineering (Imaging Dual Title)
Degree: Doctor of Philosophy
Optical coherence tomography (OCT), based on the principle of interferometry, is a fast and
non-invasive imaging modality, which has been approved by FDA for dermatologic applications.
OCT has high spatial resolution up to micrometer scale compared to traditional ultrasound imaging.
In addition, OCT can provide real-time cross-sectional images with 1 to 2 mm penetration depth,
which makes it an ideal imaging technique to assess the skin micro-morphology and pathology
without any tissue removal. Many studies have investigated the possibilities of using OCT to
evaluate dermatologic conditions, such as skin cancer, dermatitis, psoriasis, and skin damages.
Hence, OCT has tremendous potential to provide skin histological and pathological information
and assist differential diagnosis of various skin diseases. In this study, we used a swept-source
OCT with 1305 nm central wavelength to explore its advanced applications in dermatology.
This dissertation consists of four major research projects. First, we explored the feasibility
of OCT imaging for assisting real-time visualization in skin biopsy. We showed that OCT could
be used to guide and track a needle insertion in mouse skin in real-time. The structure of skin and
the movement of needle can be clearly seen on the OCT images without any time delay during the
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procedures. Next, we tested the concept of performing the punch biopsy using OCT hand-held
probe attached to a piercing tip in a phantom. We proved that using the OCT is a reliable technique
to delineate the margin of lesion in phantom. And it is possible to perform the punch biopsy with
the OCT probe. Second, we tested the performance of contrast-enhanced OCT in melanoma
detection in an in vitro study. Melanoma is the most lethal type of skin cancer. Early detection
could significantly improve the long-term survival rate of patients. In this initial study, a contrast
agent (Gal3-USGNPs) is developed by conjugating melanoma biomarker (Gal3) to ultra-small
gold nanoparticles (USGNPs). We showed that the contrast agent can differentiate B16 melanoma
cells from normal skin keratinocytes in vitro. To avoid systemic administration of USGNPs, the
third project continues to explore the enhanced topical delivery of USGNPs. In this study, we used
OCT to monitor the topical delivery of nanoparticles on pig skin over time. And the diffusion and
penetration of USGNPs in skin can be improved by applying chemical and physical enhancers
such as DMSO and sonophoresis. Finally, in addition to image the cross-sectional structure of skin,
we also aim to extract quantitative information from OCT images. The skin optical properties such
as attenuation coefficient can be measured from OCT images. We measured and compared the
skin attenuation coefficient in the skin of forehead and lateral hip, the skin of three different age
groups, and the skin of three different Fitzpatrick types. The statistical analysis showed that
epidermis has much higher attenuation coefficient than dermis. And the skin type V & VI have a
relatively lower attenuation coefficient than the other skin types.
These studies could aid the detection of skin cancer using imaging techniques and provide
some new insights into the future applications of OCT in dermatology.
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